Medytox Solutions (MMMS) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 26, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Medytox Solutions, Inc.	'
Entity Central Index Key	'0001374536	'
Document Type	'10-K	'
Document Period End Date	31-Dec-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Public Float	'	$0
Entity Common Stock, Shares Outstanding	'	0
Document Fiscal Period Focus	'FY	'
Document Fiscal Year Focus	'2013	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash	$4,141,416	$1,773,785
Accounts receivable, net	10,986,368	3,269,180
Deferred loan costs	0	77,192
Prepaid expenses and other current assets	194,137	109,697
Deferred tax assets	1,748,600	1,980,600
Assets attributable to disputed activity	1,367,796	1,367,796
Total current assets	18,438,317	8,578,250
Property and equipment, net	2,156,381	598,741
Other assets:	'	'
Intangible assets	3,190,613	550,000
Goodwill	1,425,999	1,050,912
Deposits	96,747	70,368
Total assets	25,308,057	10,848,271
Current liabilities:	'	'
Accounts payable	1,755,965	1,168,443
Accrued expenses	2,855,884	1,026,922
Loans and notes payable, related parties	0	242,100
Income tax liabilities	6,052,740	1,883,900
Disputed net income - Trident	397,918	397,918
Current portion of notes payable	3,689,554	3,154,389
Current portion of capital lease obligation	193,095	0
Liabilities attributable to disputed activity	1,104,063	1,104,063
Total current liabilities	16,049,219	8,977,735
Other liabilities:	'	'
Notes payable, net of current portion	42,107	0
Capital lease obligations, net of current portion	405,718	0
Deferred tax liabilities	41,800	36,100
Total liabilities	16,538,844	9,013,835
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock	3,000	2,953
Additional paid-in-capital	1,905,223	616,512
Deferred issuance costs	-12,500	0
Retained earnings	6,752,485	1,093,866
Total Medytox Solutions stockholders' equity	8,648,209	1,713,432
Noncontrolling interest	121,004	121,004
Total stockholders' equity	8,769,213	1,834,436
Total liabilities and stockholders' equity	25,308,057	10,848,271
Series B Preferred Stock	'	'
Stockholders' equity:	'	'
Preferred stock	1	1
Series C Preferred Stock	'	'
Stockholders' equity:	'	'
Preferred stock	$0	$100

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock shares authorized	100,000,000	100,000,000
Common stock par value	$0.00	$0.00
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	29,996,386	29,533,753
Common stock shares outstanding	29,996,386	29,533,753
Series B Preferred Stock	'	'
Preferred stock shares authorized	5,000	5,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	5,000	5,000
Preferred stock shares outstanding	5,000	5,000
Series C Preferred Stock	'	'
Preferred stock shares authorized	1,000,000	1,000,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	0	1,000,000
Preferred stock shares outstanding	0	1,000,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]	'	'
Revenues	$52,523,660	$21,076,357
Operating expenses:	'	'
Direct costs of revenue	9,570,950	2,913,169
General and administrative	13,479,879	6,112,016
Legal fees related to disputed subsidiary	976,789	325,762
Sales and marketing expenses	2,953,292	1,106,864
Bad debt expense	10,634,789	7,021,945
Depreciation and amortization	407,971	65,648
Total operating expenses	38,023,670	17,545,404
Income from operations	14,499,990	3,530,953
Other income (expense):	'	'
Other income	389	129
Gain on settlement of debt	0	348,315
Gain (loss) on settlement of assets	-27,413	2,546
Loss on legal settlement	-169,800	0
Interest expense	-474,649	-653,588
Total other income (expense)	-671,473	-302,598
Income before income taxes	13,828,517	3,228,355
Provision for income taxes	5,568,600	481,400
Net income from continuing operations	8,259,917	2,746,955
Net income (loss) from disputed activity	0	-397,918
Net income attributable to Medytox Solutions	8,259,917	2,349,037
Preferred stock dividends	2,601,298	50,000
Net income attributable to Medytox Solutions common shareholders	$5,658,619	$2,299,037
Net income per common share - Basic and diluted	$0.19	$0.07
Weighted average number of common shares outstanding during the period - Basic and diluted	29,654,703	30,795,073

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net income	$8,259,917	$2,349,037
Adjustments to reconcile net income to net cash provided by operations:	'	'
Depreciation and amortization	407,971	65,648
Stock issued for services	62,500	225
Stock-based compensation	452,500	235,001
Stock-based consulting fees	85,000	0
Increase in allowance for bad debts	2,324,045	7,021,945
Accretion of loan costs as interest	181,141	244,758
Accretion of beneficial conversion feature as interest	52,280	0
Gain on disposal of equipment	27,413	-2,546
Gain on conversion of debt	0	-348,315
Disputed net income	0	397,918
Assets attributable to disputed activity	0	753,830
Liabilities attributable to disputed activity	0	-108,463
Changes in operating assets and liabilities:	'	'
Accounts receivable	-10,041,233	-10,107,742
Prepaid expenses and other current assets	-84,440	-108,697
Deferred tax assets	232,000	-1,256,700
Security deposits	-26,379	-67,225
Accounts payable	527,571	726,831
Accrued expenses	1,827,655	840,242
Income tax liabilities	4,168,840	1,332,200
Deferred tax liabilities	5,700	36,100
Net cash provided by operating activities	8,462,481	2,004,047
Cash flows used in investing activities:	'	'
Purchase of property and equipment	-1,097,766	-491,545
Cash received in sale of property and equipment	750	25,373
Cash paid for acquisitions	-735,052	-101,000
Cash received in acquisitions	3,735	21,203
Net cash used in investing activities	-1,828,333	-545,969
Cash flows provided by (used in) financing activities:	'	'
Proceeds from the sale of common stock	286,000	0
Deferred issuance costs	-12,500	0
Deferred loan costs	-103,949	-121,950
Dividends on Series B preferred stock	-2,601,298	-50,000
Payments made on repurchase agreements	0	-385,200
Proceeds from issuance of notes payable	1,300,000	1,755,200
Payments on notes payable	-2,700,193	-971,536
Payments on capital lease obligations	-139,577	0
Proceeds from issuance of related party loans	0	413,093
Payments on related party loans	-195,000	-321,003
Common stock repurchased from lender	-100,000	-100,000
Net cash provided by (used in) financing activities	-4,266,517	218,604
Net increase in cash	2,367,631	1,676,682
Cash at beginning of year	1,773,785	97,103
Cash at end of year	4,141,416	1,773,785
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	342,672	336,039
Cash paid for taxes	1,162,060	0
Non-cash investing and financing activities:	'	'
Net liabilities (assets) acquired in acquisitions, net of cash	1,565,613	-437,329
Intangible assets	-2,640,613	-248,800
Notes payable issued	1,075,000	565,125
Noncontrolling interest	0	121,004
Property and equipment acquired with issuance of notes payable	-56,603	-101,032
Notes payable issued	56,603	101,032
Capital lease assets acquired	-322,441	0
Capital lease obligations	322,441	0
Conversion of Series C preferred stock to common stock:	'	'
Common stock	21	0
Series C preferred stock	-100	0
Additional paid in capital	79	0
Conversion of note payable to common stock:	'	'
Notes payable	0	-50,317
Common stock	0	2
Additional paid in capital	0	50,315
Related party loans forgiven:	'	'
Loans and notes payable, related parties	-47,100	0
Additional paid in capital	47,100	0
Beneficial conversion feature of convertible notes payable:	'	'
Notes payable	-55,558	0
Additional paid in capital	55,558	0
Adjustment to purchase price for Biohealth Medical Laboratory, Inc.:	'	'
Goodwill	24,913	0
Notes payable issued	-24,677	0
Accrued expenses	-236	0
Adjustment to purchase price for Medical Billing Choices, Inc.:	'	'
Goodwill	-400,000	0
Common stock	16	0
Additional paid in capital	399,984	0
Exchange of repurchase agreements and common stock to Series C preferred stock:	'	'
Common stock cancelled	0	-1,658
Series C preferred stock	0	100
Additional paid in capital	0	1,558
Repurchase agreements payable	0	-926,675
Treasury stock	0	926,675
Treasury stock retired and cancelled	'	'
Common stock cancelled	0	-823
Additional paid in capital	0	-406,877
Treasury stock	0	407,700
Common stock issued as inducement for loan:	'	'
Deferred loan costs	0	-200,000
Common stock	0	8
Additional paid in capital	$0	$199,992

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (Deficit) (USD $)	Preferred stock Non-designated	Preferred stock Series B	Preferred stock Series C	Common Stock	Additional Paid-In Capital	Treasury Stock	Deferred issuance costs	Noncontrolling Interest	Accumulated Deficit / earnings	Total
Beginning Balance, Amount at Dec. 31, 2011	'	'	'	$3,076	$515,761	($1,334,375)	'	$703,202	($1,082,285)	($1,194,621)
Beginning Balance, Shares at Dec. 31, 2011	'	'	'	30,764,800	'	'	'	'	'	'
Common stock issued as inducement for loan, Amount	'	'	'	8	199,992	'	'	'	'	200,000
Common stock issued as inducement for loan, Shares	'	'	'	80,000	'	'	'	'	'	'
Common stock repurchased from lender and cancelled, Amount	'	'	'	-4	-99,996	'	'	'	'	-100,000
Common stock repurchased from lender and cancelled, Shares	'	'	'	-40,000	'	'	'	'	'	'
Common stock repurchased under repurchase agreements cancelled, Amount	'	'	'	-823	-406,877	407,700	'	'	'	'
Common stock repurchased under repurchase agreements cancelled, Shares	'	'	'	-8,233,100	'	'	'	'	'	'
Repurchase agreements exchanged for Series C preferred stock and common stock cancelled, Amount	'	'	100	-1,658	1,558	926,675	'	'	'	926,675
Repurchase agreements exchanged for Series C preferred stock and common stock cancelled, Shares	'	'	1,000,000	-16,580,575	'	'	'	'	'	'
Common stock issued in exchange for notes payable, Amount	'	'	'	2	50,315	'	'	'	'	50,317
Common stock issued in exchange for notes payable, Shares	'	'	'	20,128	'	'	'	'	'	'
Common stock issued for services, Amount	'	'	'	2	223	'	'	'	'	225
Common stock issued for services, Shares	'	'	'	22,500	'	'	'	'	'	'
Common stock issued to executives as compensation, Amount	'	'	'	2,350	232,650	'	'	'	'	235,000
Common stock issued to executives as compensation, Shares	'	'	'	23,500,000	'	'	'	'	'	'
Series B preferred stock issued to executives as compensation, Amount	'	1	'	'	'	'	'	'	'	1
Series B preferred stock issued to executives as compensation, Shares	'	5,000	'	'	'	'	'	'	'	'
Acquisition of subsidiaries	'	'	'	'	'	'	'	121,004	'	121,004
Disputed activity	'	'	'	'	122,886	'	'	-703,202	-122,886	-703,202
Dividends on Series B preferred stock	'	'	'	'	'	'	'	'	-50,000	-50,000
Net income for the year ended	'	'	'	'	'	'	'	'	2,349,037	2,349,037
Ending Balance, Amount at Dec. 31, 2012	'	1	100	2,953	616,512	'	'	121,004	1,093,866	1,834,436
Ending Balance, Shares at Dec. 31, 2012	'	5,000	1,000,000	29,533,753	'	'	'	'	'	'
Common stock repurchased from lender and cancelled, Amount	'	'	'	-4	-99,996	'	'	'	'	-100,000
Common stock repurchased from lender and cancelled, Shares	'	'	'	-40,000	'	'	'	'	'	'
Common stock issued for services, Amount	'	'	'	3	62,497	'	'	'	'	62,500
Common stock issued for services, Shares	'	'	'	25,000	'	'	'	'	'	'
Series B preferred stock issued to executives as compensation, Shares	'	'	'	'	'	'	'	'	'	25,000
Dividends on Series B preferred stock	'	'	'	'	'	'	'	'	-2,601,298	-2,601,298
Common stock issued for cash, Amount	'	'	'	11	285,989	'	'	'	'	286,000
Common stock issued for cash, Shares	'	'	'	114,400	'	'	'	'	'	'
Common stock issued in acquisition of Medical Billing Choices, Inc., Amount	'	'	'	16	399,984	'	'	'	'	400,000
Common stock issued in acquisition of Medical Billing Choices, Inc., Shares	'	'	'	160,000	'	'	'	'	'	'
Warrants issued for settlement of subsidiary obligations	'	'	'	'	85,000	'	'	'	'	85,000
Stock options issued	'	'	'	'	452,500	'	'	'	'	452,500
Conversion of Series C preferred stock to common stock, Amount	'	'	-100	21	79	'	'	'	'	'
Conversion of Series C preferred stock to common stock, Shares	'	'	-1,000,000	203,233	'	'	'	'	'	'
Beneficial conversion feature	'	'	'	'	55,558	'	'	'	'	55,558
Capital contribution	'	'	'	'	47,100	'	'	'	'	47,100
Deferred issuance costs	'	'	'	'	'	'	-12,500	'	'	-12,500
Net income for the year ended	'	'	'	'	'	'	'	'	8,259,917	8,259,917
Ending Balance, Amount at Dec. 31, 2013	'	$1	'	$3,000	$1,905,223	'	($12,500)	$121,004	$6,752,485	$8,769,213
Ending Balance, Shares at Dec. 31, 2013	'	5,000	'	29,996,386	'	'	'	'	'	'

1_Organization_Nature_of_Busin

1. Organization, Nature of Business and Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. Organization, Nature of Business and Presentation	'
	Organization
	Medytox Solutions, Inc. (the “Company”), was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On June 22, 2011, the Company organized Medytox Medical Management Solutions Corp. ("MMMSC"), a Florida corporation, as a wholly-owned subsidiary.  MMMSC was a marketing company selling laboratory testing services to medical clinics, hospitals and physicians’ offices.   On October 15, 2013, MMMSC changed its name to Medytox Information Technology, Inc. (“MIT”). MIT provides information technology services and solutions to all subsidiaries and customers of the Company and operates from the corporate offices in West Palm Beach, Florida.
	On July 26, 2011, the Company organized Medytox Institute of Laboratory Medicine, Inc. ("MILM"), a Florida corporation, as a wholly-owned subsidiary.  MILM was organized to acquire and manage medical testing laboratories.  MILM operates from the corporate offices in West Palm Beach, Florida.
	On August 22, 2011, the Company acquired 100% of Medical Billing Choices, Inc. ("MBC"), a privately-owned North Carolina corporation, through a stock purchase agreement for cash and an installment note.  MBC operates a medical billing service for a variety of medical providers throughout the southeastern United States from offices in Charlotte, North Carolina.  Since the acquisition, MBC is the main billing company for the Company's laboratories.
	On February 6, 2012, the Company formed Medytox Diagnostics Inc. (“MDI”), a Florida corporation, as a wholly-owned subsidiary to acquire and build clinical laboratories. MDI operates from the corporate offices in West Palm Beach, Florida.
	On February 16, 2012, MDI acquired majority interest in Collectaway LLC, now known as PB Laboratories, LLC ("PB Labs"), a Florida limited liability company.   On October 31, 2012, MDI acquired the remaining noncontrolling interest in PB Labs.  As of October 31, 2012, PB Labs is a wholly-owned subsidiary of MDI.
	On March 9, 2013, the Company formed Medytox Medical Marketing & Sales, Inc. (“MMMS”), a Florida corporation, as a wholly-owned subsidiary that provides marketing for clinical laboratories that are owned by the Company.
	On December 7, 2012, MDI acquired a majority interest in Biohealth Medical Laboratory, Inc. (“Biohealth”), a Florida corporation.
	On January 1, 2013, MDI purchased 100% of the stock of Alethea Laboratories, Inc. ("Alethea").  Althea operates a licensed clinical lab in Las Cruces, New Mexico and is an enrolled Medicare provider.
	On January 29, 2013, MDI formed Advantage Reference Labs, Inc. (“Advantage”), a Florida corporation, as a wholly-owned subsidiary that will provide reference, confirmation and clinical testing services. On October 14, 2013, Advantage changed its name to EPIC Reference Labs, Inc. (“EPIC”).
	On April 4, 2013, MDI purchased 100% of the interests in International Technologies, LLC ("Tech").  In October 2013, Tech began doing business as NJ Reference Labs (“NJ Ref”). NJ Ref operates a licensed clinical lab in Waldwick, New Jersey and is an enrolled Medicare provider.
	Nature of Operations
	The Company operates in the medical services segment.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”).
	Reclassifications
	Certain items on the statement of operations for the year ended December 31, 2012 have been reclassified to conform to the current period presentation.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
2. Summary of Significant Accounting Policies	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant areas of estimate include the impairment of assets and rates for amortization, accrued liabilities, future income tax obligations and the inputs used in calculating stock-based compensation and transactions. Actual results could differ from those estimates and would impact future results of operations and cash flows.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Medytox Solutions, Inc. and its wholly-owned subsidiaries, Medytox Information Technology, Inc., Medytox Institute of Laboratory Medicine, Inc., Medical Billing Choices, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Medytox Medical Marketing & Sales, Inc., Alethea Laboratories, Inc., EPIC Reference Labs, Inc., and International Technologies, LLC, and its majority-owned subsidiary, Biohealth Medical Laboratory, Inc.  Due to the dispute with Trident and its selling shareholders (see Note – 4), the accounts of Trident Laboratories, Inc. have been excluded from consolidation.  In addition, a disputed net income reserve of $397,918 has been established as of December 31, 2012 representing all of Trident’s net income recognized by the Company since August 22, 2011, the date of acquisition.  All significant inter-company balances and transactions have been eliminated in consolidation.
	Cash and Cash Equivalents
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2013 and 2012, respectively, the Company had no cash equivalents.
	Revenue Recognition
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis and urine analysis. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Net service revenues are determined utilizing gross service revenues net of contractual allowances. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Medytox are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information. We estimate that 0% of self-pay billings will be collectible. The Company currently does not have any capitated agreements. In the remainder of the cases, Medytox is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like Medytox. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends.
	We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. Bad debt expense represents our estimate of net revenues that will ultimately be uncollectable and is based upon our analysis of historical payment rates by specific payor groups on a monthly basis with primary weight being given to the most recent trends; this approach allows bad debt to more accurately adjust to short-term changes in the business environment. These two calculations are routinely analyzed by Medytox on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.
	Contractual Allowances and Doubtful Accounts Policy
	Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectibility of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectibility of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense within selling, general and administrative expenses. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.
	As of December 31, 2013 and 2012, management recorded allowances for uncollectible accounts in the amount of $3,621,814 and $1,297,769, respectively.  Bad debt expense was $10,634,789 and $7,021,945 for the years ended December 31, 2013 and 2012, respectively.
	Impairment or Disposal of Long-Lived Assets
	The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.  The Company did not recognize any impairment losses for the years ended December 31, 2013 and 2012.
	Fair Value of Financial Instruments
	The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.
	ASC 820 “Fair Value Measurements and Disclosures” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) a reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means; and
	Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013 and 2012. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.
	The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.
	As of December 31, 2013 and 2012 the fair values of the Company’s financial instruments approximate their historical carrying amount.
	Advertising
	The costs of advertising are expensed as incurred.  Advertising expense was $21,550 and $111,691 for the years ended December 31, 2013 and 2012, respectively.  Advertising expenses are included in the Company’s operating expenses.
	Stock Based Compensation
	The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in stockholders' equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.
	The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.
	Income Taxes
	Income taxes are accounted for under the liability method of accounting for income taxes.  Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.  Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled.  The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs.  Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.
	The FASB has issued ASC 740 “Income Taxes”.  ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements.  This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.
	As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of December 31, 2013.
	Basic and Diluted Income Per Share
	The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations.  Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period.  Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method.  In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.  Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.  As of December 31, 2013, there were a total of 23,170,000 stock options outstanding to purchase shares of common stock, 346,400 warrants outstanding to purchase shares of common stock, a $100,000 convertible debenture convertible into 40,000 shares of the Company’s common stock, and $500,000 of convertible notes payable convertible into shares of the Company’s common stock at a 10% discount to the average market price for the thirty days prior to conversion.  However, these potentially dilutive shares are considered to be anti-dilutive and are therefore not included in the calculation of income per share.
	Segment Information
	In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of December 31, 2013 and 2012.

3_Recent_Accounting_Pronouncem

3. Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]	'
3. Recent Accounting Pronouncements	'
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2013-04,”Liabilities (Topic 405)”, which provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. ASU 2013-04 is effective for fiscal years beginning after December 15, 2013. We do not believe the adoption of ASU 2013-04 will have a material effect on the Company’s financial statements.
	In February 2013, the FASB issued ASU 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” ASU 2013-02 requires disclosure of the amounts reclassified out of each component of accumulated other comprehensive income and into net earnings during the reporting period and is effective for reporting periods beginning after December 15, 2012. We do not believe the adoption of ASU 2013−02 will have a material impact on the measurement of net earnings or other comprehensive income.
	In December 2011, the FASB issued ASU 2011-11, “Disclosures about Offsetting Assets and Liabilities” and in January 2013, the FASB issued ASU 2013-01, “Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities”. ASU 2011-11, as clarified, enhances disclosures surrounding offsetting (netting) assets and liabilities. The clarified standard applies to derivatives, repurchase agreements and securities lending transactions and requires companies to disclose gross and net information about financial instruments and derivatives eligible for offset and to disclose financial instruments and derivatives subject to master netting arrangements in financial statements. The clarified standard did not have a material effect on our financial position or results of operations.
	In October 2012, the FASB issued ASU 2012-04, “Technical Corrections and Improvements” in Accounting Standards Update No. 2012-04. The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this update is effective for fiscal periods beginning after December 15, 2012. The adoption of ASU 2012-04 did not have a material impact on our financial position or results of operations.
	Management does not believe any recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s present or future financial statements.

4_Disputed_Subsidiary

4. Disputed Subsidiary	12 Months Ended
	Dec. 31, 2013
Disputed Subsidiary Tables	'
4. Disputed Subsidiary	'
	On July 2, 2013, a jury awarded our wholly-owned subsidiary, Medytox Institute of Laboratory Medicine, Inc. ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. ("Trident"), and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for Mr. Hawley's defamatory postings on the internet.  The jury rejected every claim made against the MILM parties. Trident’s appeal has been dismissed and the appeals of the shareholders are pending.
	The case arose from the August 22, 2011 agreement among MILM and Trident and its shareholders pursuant to which MILM was to acquire 81% of Trident.  On January 17, 2012, Trident notified MILM that it was rescinding the agreement.  As a result, MILM filed suit against Trident and its shareholders in Florida Circuit Court in Broward County.  The jury found that Trident and its shareholders breached the agreement and failed to perform their obligations thereunder.
	Legal fees related to the lawsuit were $976,789 and $325,762 for the years ended December 31, 2013 and 2012, respectively.
	The Company has not received any financial statements of Trident since August 31, 2012.  These consolidated financial statements were prepared without the missing activity.  Management believes that the missing activity is immaterial to the consolidated financial statements as a whole.  The Company established a disputed net income reserve of $397,918 as of December 31, 2012, representing all of Trident's net income recognized by the Company since August 22, 2011, the date of acquisition.  The assets and liabilities of Trident have been condensed and presented as assets, or liabilities, attributable to disputed activity in the December 31, 2013 and 2012 consolidated balance sheets.  A separate $389,135 of commissions payable on Trident sales is included in liabilities attributable to disputed activity as of December 31, 2013 and 2012.
	Assets and liabilities of the disputed subsidiary as of December 31, 2013 and 2012 were as follows:
	Total assets	$	1,367,796
	Total liabilities	$	1,104,063

5_LongLived_Assets

5. Long-Lived Assets	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
5. Long-Lived Assets	'
	Property and equipment at December 31, 2013 and 2012 consisted of the following:
		December 31,
		2013			2012
	Medical equipment	$	655,125		$	269,931
	Equipment		111,265			37,140
	Equipment under capital leases		980,948			–
	Furniture		206,587			66,606
	Leasehold improvements		243,983			47,197
	Vehicles		177,534			70,828
	Computer equipment		235,507			85,478
	Software		285,175			196,711
			2,896,124			773,891
	Less accumulated depreciation		(739,743	)		(175,150	)
	Property and equipment, net	$	2,156,381		$	598,741
	Depreciation of property and equipment was $407,971 and $65,648 for the years ended December 31, 2013 and 2012, respectively.
	The Company’s management has performed a valuation of the identifiable intangible assets, including medical licenses, of Alethea Laboratories, Inc. and International Technologies, LLC (see Note – 13 Business Combinations). As a result, the Company has recorded medical licenses acquired from all acquisitions in the amount of $3,190,613 and $550,000 as intangible property as of December 31, 2013 and 2012, respectively.  The medical licenses include licenses for Medicare and Medicaid, COLA Laboratory Accreditation, Clinical Laboratory Improvement Amendments (CLIA), and State of Florida (AHCA) Clinical Laboratory Licenses, and have indefinite lives.  As such, there was no amortization of intangible assets for the years ended December 31, 2013 and 2012.
	Management periodically reviews the valuation of long-lived assets for potential impairments.  Management has not recognized an impairment of these assets to date, and does not anticipate any negative impact from known current business developments.

6_Accrued_Expenses

6. Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
6. Accrued Expenses	'
	Accrued expenses at December 31, 2013 and 2012 consisted of the following:
		December 31,
		2013		2012
	Commissions payable	$	277,731	$	–
	Dividends payable		360,726		–
	Accrued payroll and related liabilities		114,471		283,490
	Accrued bonuses		1,900,000		500,000
	Accrued interest		46,842		146,943
	Other accrued expenses		156,114		96,489
	Accrued expenses	$	2,855,884	$	1,026,922
	The accrual of bonuses was approved by the Company’s board of directors on February 6, 2014.

7_Notes_Payable

7. Notes Payable	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
7. Notes Payable	'
	The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties.  At December 31, 2013 and 2012, notes payable consisted of the following:
			December 31,
			2013			2012
	Convertible debenture for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%.  Interest only payments are payable monthly.  The note is convertible at $2.50 per share. The due date of the note was extended from October 31, 2013 to February 5, 2014 by the lender.  This note is subordinated to the loan from TCA Global Credit Master Fund, L.P. ("TCA") and is secured by the assets of the Company, Medytox Information Technology Inc. ("MIT") and Trident.		$	100,000		$	500,000
	Loan for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%.  Interest and principal were payable in 10 equal payments ending August 31, 2013. This note was subordinated to the loan from TCA and was secured by the assets of the Company, MIT and Trident.			–			150,000
	Acquisition note to former shareholders of Medical Billing Choices, Inc. ("MBC") in the amount of $750,000, with interest at 6%, payable by August 22, 2013.			–			449,512
	Loan from TCA.  Principal of $2,475,000 and $1,725,000, respectively, payable by January 15, 2014. The note was extended from January 15, 2014 to September 15, 2014, and is secured by all assets of the Company and its subsidiaries (other than Trident and MBC). See "TCA Global" below.			2,475,000			1,725,000
	Acquisition note to former member of PB Laboratories, LLC for 50.5% ownership, in the amount of $200,000 at 6% interest, with payments of $50,000 quarterly starting May 17, 2012.			–			50,000
			December 31,
			2013			2012
	Acquisition note to former member of PB Laboratories, LLC for 49.5% ownership, in the amount of $200,000 at 0% interest, with payments of $50,000 quarterly starting January 31, 2013.			–			150,000
	Acquisition note to former shareholder of Biohealth Medical Laboratory, Inc. for 50.5% ownership, in the amount of $165,125 at 0% interest, with payments of $75,000 due quarterly starting February 7, 2013 and a final payment of $15,125 due on August 7, 2013.  In May 2013, a final settlement was reached with the former shareholder and the remaining balance of $24,677 as of May 31, 2013 was discharged.			–			99,677
	Short-term note from affiliate, non-interest bearing and is due on demand.			–			30,200
	Acquisition note No.1 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.			150,000			–
	Acquisition note No. 2 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.			150,000			–
	Loan from former shareholders of Alethea Laboratories, Inc. in the amount of $344,650 at 4% interest, with principal payments of $24,618 due monthly starting March 15, 2013.			98,471			–
	Commercial loan with a finance company, dated December 20, 2012, in the original amount of $18,249 and bearing interest at 12.59%.  Principal and interest payments in the amount of $364 are payable for 72 months ending on January 3, 2019. This note is secured by a lien on a vehicle with a carrying value of $16,623 at December 31, 2013.			15,845			–
	Commercial loan with a finance company, dated November 15, 2012, in the original amount of $18,008 and bearing interest at 15.07%.  Principal and interest payments in the amount of $384 are payable for 72 months ending on November 30, 2018. This note is secured by a lien on a vehicle with a carrying value of $16,430 at December 31, 2013.			16,279			–
	Commercial loan with a finance company, dated November 28, 2012, in the original amount of $20,345 and bearing interest at 8.99%.  Principal and interest payments in the amount of $368 are payable for 72 months ending on January 12, 2019. This note is secured by a lien on a vehicle with a carrying value of $18,300 at December 31, 2013.			17,676			–
			December 31,
			2013			2012
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest, due January 17, 2014.  The note is convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $1,639 at December 31, 2013.			248,361			–
	Acquisition convertible note No. 2 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest, due January 17, 2014.  The note is convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $1,639 at December 31, 2013.			248,361			–
	Loan from former member of International Technologies, LLC in the remaining amount of $416,667 at the date of acquisition, at 1% interest, with principal payments of $83,333 due quarterly starting June 7, 2013.			166,668			–
	Loan from former member of International Technologies, LLC in the remaining amount of $112,500 at the date of acquisition, at 1% interest, with principal payments of $22,500 due quarterly starting June 7, 2013.			45,000			–
				3,731,661			3,154,389
	Less current portion			(3,689,554	)		(3,154,389	)
	Notes payable, net of current portion		$	42,107		$	–
	TCA Global
	On May 14, 2012, the Company borrowed $550,000 from TCA Global Credit Master Fund, LP (the "Lender") pursuant to the terms of the Senior Secured Revolving Credit Facility Agreement, dated as of April 30, 2012 (the "Credit Agreement"), among Medytox, MMMS, MDI, PB Labs and the Lender.  The funds were used for general corporate purposes.  Under the Credit Agreement, Medytox may borrow up to an amount equal to the lesser of 80% of its Eligible Accounts (as defined in the Credit Agreement) and the revolving loan commitment, which initially was $550,000.
	Medytox could request that the revolving loan commitment be raised by various specified amounts at specified times, up to an initial maximum of $4,000,000.  In each case, whether to agree to any such increase in the revolving loan commitment was in the Lender's sole discretion.
	On August 9, 2012, the Company borrowed an additional $525,000 in a second round of funding.  These additional funds were also used for general corporate purposes.  In this second round of funding, certain changes were made to the terms of the Credit Agreement:
		·	the revolving loan commitment was increased from $550,000 to $1,100,000 and was subject to further increase, up to a maximum of $4,000,000, in the Lender's sole discretion;
		·	the maturity date of the loan was extended to February 8, 2013 from the original maturity date of November 30, 2012 (subject to the Lender's continuing ability to call the loan upon 60 days written notice); and
		·	a prepayment penalty was added of 5% if substantially all of the loan is prepaid between 91 and 180 days prior to the maturity date, or 2.50% if substantially all of the loan is prepaid within 90 days of the maturity date.
	On December 4, 2012, the Company borrowed an additional $650,000 in a third round of funding.  These additional funds were used for general corporate purposes.  In this third round of funding, certain additional changes were made to the terms of the Credit Agreement:
		·	the revolving loan commitment was increased from $1,100,000 to $1,725,000 and was subject to further increase, up to a maximum of $15,000,000, in the Lender's sole discretion;
		·	the maturity date of the loan was extended to September 3, 2013 from the previous maturity date of February 8, 2013 (subject to the Lender's continuing ability to call the loan upon 60 days written notice); and
		·	a covenant was added to require that any subsidiary that is formed, acquired or otherwise becomes a subsidiary must guarantee the loan and pledge substantially all of its assets as security for the loan.
	On March 4, 2013, Medytox borrowed an additional $800,000 from the Lender pursuant to the terms of Amendment No. 3 to Senior Secured Revolving Credit Facility Agreement, dated as of February 28, 2013 ("Amendment No. 3"). These additional funds were used in accordance with management's discretion. In connection with Amendment No. 3, Advantage Reference Labs, Inc., a newly-formed wholly-owned subsidiary of Medytox, now known as EPIC Reference Labs, Inc. ("EPIC"), entered into a Guaranty Agreement to guaranty the TCA loan and a Security Agreement to pledge substantially all its assets to secure its guaranty.
	In connection with Amendment No. 3, Medytox executed an Amended and Restated Revolving Promissory Note, due September 4, 2013, in the amount of $2,525,000.
	On July 15, 2013, Medytox borrowed an additional $500,000 from the Lender pursuant to the terms of Amendment No. 4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013 ("Amendment No. 4"). These additional funds were used in accordance with management's discretion. In connection with Amendment No. 4, each of International Technologies, LLC ("International") and Alethea Laboratories, Inc. ("Alethea"), wholly-owned subsidiaries of Medytox, entered into a Guaranty Agreement to guaranty the TCA loan and a Security Agreement to pledge substantially all of its assets to secure its guaranty. The maturity date of the loan was extended to January 15, 2014 from the previous maturity date of September 3, 2013 (subject to the Lender’s continuing ability to call the loan upon 60 days written notice).
	In connection with Amendment No. 4, Medytox executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. Except as amended through Amendment No. 4, the terms of the Credit Agreement remain in full force and effect. On August 12, 2013, the Company made a payment of $550,000 on the note. The note has been extended by the lender from January 15, 2014 to September 15, 2014.
	Deferred Loan Costs
	The Company has incurred certain loan costs as inducement for loans and has recorded them as deferred loan costs.  The loan costs are amortized as interest expense on a straight-line basis over the life of the loan. Deferred loan costs at December 30, 2013 and 2012 consisted of the following:
			December 31,
			2013			2012
	Deferred loan costs		$	425,899		$	321,950
	Less accumulated accretion as interest			(425,899	)		(244,758	)
	Deferred loan costs, net		$	-0-		$	77,192

8_Related_Party_Transactions

8. Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
8. Related Party Transactions	'
	William Forhan, the Chief Executive Officer, and a director and shareholder of the Company, had advanced loans to the Company for the payment of certain operating expenses.  The loans were non-interest bearing and were due on demand. The amount outstanding to Mr. Forhan was $57,100 at December 31, 2012. During the year ended December 31, 2013, $10,000 was paid and the remaining $47,100 was released by Mr. Forhan. The $47,100 is recorded as a capital contribution as additional paid in capital.
	Alcimede LLC, of which a shareholder of the Company is the managing member, had advanced loans to the Company for the payment of certain operating expenses.  The loans were non-interest bearing and were due on demand. The amount outstanding to Alcimede was $85,000 at December 31, 2012. During the year ended December 31, 2013, the $85,000 was paid along with a one-time interest charge of $18,417. Alcimede was paid $240,000 and $240,000 for consulting fees pursuant to a consulting agreement for the years ended December 31, 2013 and 2012, respectively. The Company reimbursed Alcimede $520,334 and $71,422 for certain operating expenses and asset purchases paid by Alcimede on the Company’s behalf in the years ended December 31, 2013 and 2012, respectively.
	A selling shareholder of MBC had advanced loans to the Company for the payment of certain operating expenses.  The loans were non-interest bearing and were due on demand. The amount outstanding to the selling shareholder was $100,000 at December 31, 2012 and was paid during the year ended December 31, 2013.
	On September 10, 2012, the Company entered into an Asset Purchase Agreement with DASH Software, LLC (“DASH”) for the purchase of certain software utilized by the Company in its operations for $150,000. Sharon Hollis, a Vice President and shareholder of the Company, is the managing member of DASH. During the years ended December 31, 2013 and 2012, the Company paid $33,070 and $116,930 to DASH, respectively, pursuant to the Asset Purchase Agreement. As of December 31, 2013, the purchase is fully paid.
	In connection with the Company's acquisition of MBC, Dr. Thomas Mendolia, the Chief Executive Officer of the Company's Laboratories and a shareholder, entered into an agreement with the selling shareholders of MBC to receive 20% of the purchase price of MBC as it was paid by the Company and 0.88% of the gross collections that MBC collected for the Company.  Pursuant to this agreement, Dr. Mendolia received $29,625 for the year ended December 31, 2011, $90,152 during the year ended December 31, 2012 and $103,583 during the six months ended June 30, 2013 for a total of $223,360. Pursuant to the completion of the acquisition of MBC on July 22, 2013, the Company and Dr. Mendolia agreed that the $223,360 would be paid back to MBC and payment was received in July 2013. The Company reimbursed Dr. Mendolia $252,841 and $48,786 for certain operating expenses and asset purchases paid by Dr. Mendolia on the Company’s behalf in the years ended December 31, 2013 and 2012, respectively.
	At December 31, 2011, senior management had deferred compensation of $291,766.   During the year ended December 31, 2012, $15,000 was paid and the remaining $276,766 was released by senior management.  The $276,766 is included in gain on settlement of debt (see Note 11).

9_Capital_Lease_Obligations

9. Capital Lease Obligations	12 Months Ended
	Dec. 31, 2013
Capital Lease Obligations [Abstract]	'
9. Capital Lease Obligations	'
	The Company leases various assets under capital leases expiring in 2020 as follows:
		December 31,
		2013				2012
	Medical equipment	$	980,948			$	–
	Less accumulated depreciation		(364,726	)			–
	Net	$	616,222			$	–
	Depreciation expense on assets under capital leases was $137,306 for the year ended December 31, 2013.
	Aggregate future minimum rentals under capital leases are as follows:
	December 31,
	2014			$	203,865
	2015				208,612
	2016				82,058
	2017				35,575
	2018				35,575
	Thereafter				68,186
	Total				633,871
	Less interest:				35,058
	Present value of minimum lease payments				598,813
	Less current portion of capital lease obligations				193,095
	Capital lease obligations, net of current portion			$	405,718

10_Stockholders_Equity

10. Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

'

10. Stockholders' Equity

'

Authorized Capital

The Company has 500,000,000 authorized shares of Common Stock at $0.0001 par value and 100,000,000 authorized shares of Preferred Stock at a par value of $0.0001.

On October 1, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 5,000 shares of Series B Non-convertible Preferred Stock, at $0.0001 par value per share.  The Series B shares do not include any voting rights and allow for monthly dividends in an amount equal to the sum of 1) 10% of the amount of gross sales in excess of $1 million collected in the ordinary course of business, not to exceed $150,000, and 2) 15% of the amount of gross sales in excess of $2.5 million collected in the ordinary course of business.

On October 7, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 1,000,000 shares of Series C Convertible Preferred Stock, at $0.0001 par value per share.  The Series C shares were convertible into shares of Common Stock by the quotient of 1 divided by the product of 0.80 multiplied by the market price of the Company’s Common Stock at the date of conversion.  The Series C shares also included voting rights of 25 votes for every share of Series C Preferred Stock and were entitled to dividends at the same time any dividend was paid or declared on any shares of the Company’s Common Stock.

Preferred Stock

During the year ended December 31, 2012, the Company issued 5,000 shares of Series B Preferred Stock to executives as compensation.  The shares were valued at par totaling $1 and charged to operations.

During the year ended December 31, 2012, the Series B Preferred shareholders agreed to limit their dividend for 2012 to a total of $50,000.  The dividend was paid on December 6, 2012.  If the dividend had not been limited, the Series B shareholders would have received $281,430. During the year ended December 31, 2013, the Series B preferred shareholders earned dividends totaling $2,601,298, of which $360,726 was due and payable at December 31, 2013.

During the year ended December 31, 2012, the Company issued 1,000,000 shares of Series C Preferred Stock in exchange for $926,675 of repurchase agreements and cancelled 16,580,575 shares of treasury stock. Under the terms of the certificate of designation, the 1,000,000 shares of Series C preferred shares were mandatorily converted into 203,233 shares of the Company’s common stock on December 31, 2013.

Common Stock

During the year ended December 31, 2011, the Company offered promissory notes in the total amount of $1,484,475 to a number of shareholders in exchange for retiring a total of 27,114,175 shares of common stock.  Some of these shares had been returned and were listed as treasury stock at December 31, 2011.  The promissory notes were recorded as other liabilities on the balance sheet. As the notes were paid off, the associated treasury stock was cancelled.

During the year ended December 31, 2011, the Company paid a total of $172,600 on the promissory notes and cancelled 2,300,500 shares of the treasury stock at a value of $150,100.

During the year ended December 31, 2012, the Company paid a total of $385,200 on the promissory notes and cancelled 8,233,100 shares of treasury stock at a value of $407,700.  Also during the year ended December 31, 2012, the Company exchanged the remaining $926,675 of the promissory notes for 1,000,000 shares of Series C preferred stock and cancelled 16,580,575 shares of the treasury stock at a value of $926,675.

During the year ended December 31, 2012, the Company issued 80,000 shares of its restricted Common Stock for corporate advisory and investment banking services in connection with an additional funding at a value of the services received of $200,000.  Also during the same period, the Company repurchased and cancelled 40,000 shares of the restricted Common Stock from the lender for a total of $100,000.

During the year ended December 31, 2012, the Company issued 20,128 shares of its restricted Common Stock in conversion of a note payable of $50,317.

During the year ended December 31, 2012, the Company issued 22,500 shares of its restricted Common Stock for consulting services at a value of $225.

During the year ended December 31, 2012, the Company issued 23,500,000 shares of its restricted Common Stock for compensation to executives at a value of $235,000.

During the year ended December 31, 2013, the Company issued Units consisting of a total of 46,400 shares of its restricted Common Stock and warrants to purchase an additional 46,400 shares of restricted Common Stock at an exercise price of $2.50 to nine investors for $116,000 cash ($2.50 per unit) in private placements.

During the year ended December 31, 2013, the Company issued 68,000 shares of its restricted Common Stock to two investors for $170,000 cash ($2.50 per share) in private placements.

During the year ended December 31, 2013, the Company repurchased the remaining 40,000 shares of its Common Stock from the Lender for $100,000 and cancelled the shares.

During the year ended December 31, 2013, the Company issued 25,000 shares of its restricted common stock to an employee in lieu of cash compensation. The shares were valued at $2.50 per share, based on the price of shares sold to investors, for a total of $62,500.

During the year ended December 31, 2013, the Company issued an aggregate of 160,000 shares of its restricted Common Stock to the former shareholders of its subsidiary, Medical Billing Choices, Inc. (“MBC”) in accordance with an amendment to the Agreement dated August 22, 2011, pursuant to which the Company had acquired MBC. See Note 13 – Business Combinations. The shares were valued at $2.50 per share, based on the price of shares sold to investors, for a total of $400,000.

During the year ended December 31, 2013, pursuant to the terms of the certificate of designation, the Company issued 203,233 shares of its restricted Common Stock in the mandatory conversion of the 1,000,000 shares of its Series C preferred stock.

2013 Equity Plan

On September 25, 2013, the Company’s board of directors approved and adopted the Medytox Solutions, Inc. 2013 Incentive Compensation Plan (the “2013 Plan”). The 2013 Plan was approved by a majority of stockholders of the Company on November 22, 2013. The 2013 Plan provides for the grant of shares of common stock, options, performance shares, performance units, restricted stock, stock appreciation rights and other awards. No awards of any kind under the 2013 Plan have been granted as of December 31, 2013.

Stock Options

The following summarizes option activity for the years ended December 31, 2013 and 2012:

Weighted

Common Stock Options Outstanding

average

Employees and

exercise

Directors

Non-employees

Total

price

Outstanding at December 31, 2011

–

400,000

400,000

4.5

Options granted

19,300,000

3,020,000

22,320,000

$

5.66

Options exercised

–

–

–

–

Options cancelled or expired

(1,000,000

)

(400,000

)

(1,400,000

)

3.43

Outstanding at December 31, 2012

18,300,000

3,020,000

21,320,000

5.79

Options granted

1,850,000

–

1,850,000

3.24

Options exercised

–

–

–

–

Options cancelled or expired

–

–

–

–

Balance at December 31, 2013

20,150,000

3,020,000

23,170,000

$

5.33

The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at December 31, 2013:

Options outstanding

Options vested and exercisable

Weighted

average

Weighted

Weighted

remaining

average

Aggregate

average

Aggregate

Number

contractual

exercise

intrinsic

Number

exercise

intrinsic

Exercise price

outstanding

life (years)

price

value

vested

price

value

$

2.5

7,550,000

3.66

$

2.5

$

–

7,450,000

$

2.5

$

–

$

5

6,600,000

3.97

$

5

–

6,500,000

$

5

–

$

10

6,000,000

9.01

$

10

–

6,000,000

$

10

–

20,150,000

$

5.55

$

–

19,950,000

$

5.57

$

–

During the year ended December 31, 2012, the Company issued 19,300,000 options to employees with a grant date fair value of $0.00 as there was no market value for the stock.  1,000,000 options were cancelled during the year ended December 31, 2012.  All of the options granted were fully vested upon their grant. Stock option expense for employees was $0 for the year ended December 31, 2012.

The Company estimated the fair value of employee stock options using the Black-Scholes Option Pricing Model. The fair value of employee stock options is expensed upon vesting of the awards. The fair value of employee stock options was estimated using the following assumptions:

Stock price

$0.00

Expected term

1 to 5 years

Expected volatility

29 to 30%

Risk-free interest rate

0.25 to 0.72%

Dividend yield

0

During the year ended December 31, 2013, the Company issued options to purchase a total of 600,000 shares of the Company’s common stock to two directors. These options have contractual lives of four years and were valued at an average grant date fair value of $0.20 per option, or $120,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Contractual term

4 years

Expected volatility

26.48%

Risk free interest rate

0.54%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. Vested amount of the options of $80,000 was expensed as stock-based compensation for the year ended December 31, 2013. As of December 31, 2013, there was unrecognized compensation costs of $40,000 related to these stock options. The Company expects to recognize those costs over a weighted average period of .55 years as of December 31, 2013. Future option grants will increase the amount of compensation expense to be recorded in these periods.

During the year ended December 31, 2013, the Company issued options to purchase a total of 1,250,000 shares of the Company’s common stock to an employee. These options have contractual lives of three to five years and were valued at an average grant date fair value of $0.30 per option, or $372,500, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Contractual term

3 to 5 years

Expected volatility

29.50%

Risk free interest rate

0.32% to 0.47%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. All of the options were fully vested upon their grant and the fair value of the options of $372,500 was expensed as stock-based compensation for the year ended December 31, 2013.

The following table summarizes information with respect to stock options outstanding and exercisable by non-employees at December 31, 2013:

Options outstanding

Options vested and exercisable

Weighted

average

Weighted

Weighted

remaining

average

Aggregate

average

Aggregate

Number

contractual

exercise

intrinsic

Number

exercise

intrinsic

Exercise price

outstanding

life (years)

price

value

vested

price

value

$

2.5

1,020,000

3.94

$

2.5

$

–

1,020,000

$

2.5

$

–

$

5

1,000,000

4

$

5

–

1,000,000

$

5

–

$

10

1,000,000

9.01

$

10

–

1,000,000

$

10

–

3,020,000

$

5.81

$

–

3,020,000

$

5.81

$

–

During the year ended December 31, 2012, the Company issued 3,020,000 options to non-employees with a grant date fair value of $0.00 as there was no market value for the stock.  400,000 options were cancelled during the year ended December 31, 2012.  All of the options granted were fully vested upon their grant.  Stock option expense for non-employees was $0 and $0 for the years ended December 31, 2013 and 2012.

The Company estimated the fair value of non-employee stock options using the Black-Scholes Option Pricing Model. The fair value of non-employee stock options is expensed upon vesting of the awards. The fair value of non-employee stock options was estimated using the following assumptions:

Stock price

$0.00

Expected term

2 to 10 years

Expected volatility

29 - 30%

Risk-free interest rate

0.25 – 1.78%%

Dividend yield

0

Warrants

The following table summarizes warrant transactions for the year ended December 31, 2013:

Weighted

Weighted

average

average

remaining

Aggregate

Number

exercise

contractual

intrinsic

of warrants

price

term (years)

value

Outstanding at December 31, 2012

–

$

–

$

–

Granted in 2013

346,400

$

3.22

Outstanding at December 31, 2013

346,400

$

3.22

0.94

$

–

Exercisable at December 31, 2013

346,400

$

3.22

0.94

$

–

Weighted Average Grant Date Fair Value

$

0.25

During the year ended December 31, 2013, the Company issued warrants to purchase a total of 46,400 shares of the Company’s common stock in conjunction with sales of Units. These warrants have contractual lives of one year and were valued at a grant date fair value of $-0- per warrant using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$0.01

Contractual term

1 year

Expected volatility

29.13%

Risk free interest rate

0.15%

Dividend yield

0

During the year ended December 31, 2013, the Company issued warrants to purchase a total of 300,000 shares of the Company’s common stock to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants have contractual lives of two years and were valued at an average grant date fair value of $0.283 per warrant, or $85,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price

$2.50

Contractual term

2 years

Expected volatility

29.13%

Risk free interest rate

0.27%

Dividend yield

0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. The $85,000 was expensed as stock-based consulting fees for the year ended December 31, 2013.

11_Settlement_of_Debt

11. Settlement of Debt	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
11. Settlement of Debt	'
	During the year ended December 31, 2012, two parties, our Chief Executive Officer and a former officer and director of the Company, released the Company of remaining contractual deferred compensation amounts due to them totaling $276,766 which were recorded in accrued liabilities at December 31, 2011.
	During the year ended December 31, 2012, three parties, former vendors of Casino Players, Inc., released the Company of remaining contractual amounts due to them totaling $59,000 which were recorded in accounts payable at December 31, 2011.
	During the year ended December 31, 2012, three parties, former employees of MMMS, released the Company of remaining contractual amounts due to them totaling $12,549 which were recorded in accounts payable at December 31, 2011.

12_Income_Taxes

12. Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
12. Income Taxes	'
	Significant components of the income tax provision are summarized as follows:
		Year Ended December 31,
		2013			2012
	Current provision:
	Federal	$	5,834,600		$	1,702,200
	State		1,027,500			181,700
	Deferred provision:
	Federal		(1,168,700	)		(1,267,200	)
	State		(124,800	)		(135,300	)
		$	5,568,600		$	481,400
	A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate on income before income taxes for the years ended December 31, 2013 and 2012 is as follows:
		Year Ended December 31,
		2013			2012
	Expected federal income tax at 34% statutory rate		34.00%			34.00%
	State income taxes		4.30%			3.60%
	Permanent differences		2.00%			3.50%
	Change in valuation allowance		0.00%			-26.00%
			40.30%			15.10%
	The Company provides for income taxes using the liability method in accordance with FASB ASC Topic 740 “Income Taxes”. Deferred income taxes arise from the differences in the recognition of income and expenses for tax purposes. Deferred tax assets and liabilities are comprised of the following at December 31, 2013 and 2012:
		December 31,
		2013			2012
	Deferred income tax assets:
	Allowance for bad debts	$	1,362,900		$	1,980,600
	Accrued compensation		385,700			–
	Stock options		170,300			–
	Total deferred income tax assets	$	1,918,900		$	1,980,600
	Deferred income tax liabilities:
	Property and equipment	$	(76,100	)	$	–
	Intangible amortization		(136,000	)		(36,100	)
	Total deferred income tax liabilities	$	(212,100	)	$	(36,100	)
	Net deferred income taxes:
	Current		1,748,600			1,980,600
	Non-current		(41,800	)		(36,100	)
		$	1,706,800		$	1,944,500
	Management has reviewed the provisions regarding assessment of their valuation allowance on deferred tax assets and based on that criteria determined that it will have sufficient taxable income to realize those assets. Therefore, management has assessed the realization of the deferred tax assets and has determined that it is more likely than not that they will be realized.
	The Company recognizes the consolidated financial statement impact of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than–not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
	The Company is subject to income taxes in the U.S. federal jurisdiction and the states of Florida, North Carolina, New Mexico and New Jersey. The tax regulations within each jurisdiction are subject to interpretation of related tax laws and regulations and require significant judgment to apply.  As of December 31, 2013, tax years 2012, 2011, 2010, 2009, 2008, 2007, 2006 and 2005 remain open for IRS audit. The Company has received no notice of audit from the IRS for any of the open tax years.

13_Business_Combinations

13. Business Combinations	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
13. Business Combinations	'
	The Company completed two acquisitions during the year ended December 31, 2013 and two during the year ended December 31, 2012.  The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 “Business Combinations“.  As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given has been recorded as a gain on acquisition or as goodwill.
	Goodwill was attributable to the following subsidiaries as of December 31, 2013 and December 31, 2012:
		December 31,
		2013			2012
	Medical Billing Choices, Inc.	$	1,202,112		$	802,112
	PB Laboratories, LLC		107,124			107,124
	Biohealth Medical Laboratory, Inc.		116,763			141,676
		$	1,425,999		$	1,050,912
	International Technologies, LLC
	On April 4, 2013, the Company, through its subsidiary, Medytox Diagnostics, Inc. (“MDI”), agreed to purchase 100% of the membership interests of International Technologies, LLC ("Intl Tech") from two unrelated parties for cash of $127,000 and two convertible debentures in a total amount of $500,000.  The debentures bear interest at 5%, are due on January 17, 2014 and are convertible at any time after 90 days from the date of issuance at a conversion price of a 10% discount to the average market price of the Company’s common stock for the 30 days prior to the conversion.
	The following table summarizes the consideration given for Intl Tech and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date.
	Consideration Given:
	Cash	$	127,000
	Amount due from International Technologies, LLC		483,052
	Acquisition notes		500,000
	Total Consideration	$	1,110,052
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	1,703
	Property and equipment, net		31,649
	Accounts payable and accrued expenses		(59,462	)
	Notes payable		(529,167	)
	Identified intangible assets		1,665,329
	Total identifiable net assets		1,110,052
	Goodwill and unidentified intangible assets		–
		$	1,110,052
	Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
	Alethea Laboratories, Inc.
	On January 1, 2013, the Company, through its subsidiary, MDI, agreed to purchase 100% of Alethea Laboratories, Inc. ("Alethea") from two unrelated parties for cash of $125,000 and two non-interest bearing installment notes in a total amount of $575,000.  The notes are being paid in $50,000 quarterly installments beginning on April 1, 2013.
	The following table summarizes the consideration given for Alethea and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date.
	Consideration Given:
	Cash	$	125,000
	Acquisition notes		575,000
	Total Consideration	$	700,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	2,032
	Property and equipment, net		92,498
	Capital lease assets, net		392,817
	Accounts payable		(2,032	)
	Note payable		(344,650	)
	Capital lease obligation		(415,949	)
	Identified intangible assets		975,284
	Total identifiable net assets		700,000
	Goodwill and unidentified intangible assets		–
		$	700,000
	Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
	Medical Billing Choices, Inc.
	On July 12, 2013, the Company and the two selling shareholders amended the Agreement, dated August 22, 2011, pursuant to which the Company had acquired Medical Billing Choices, Inc. (“MBC”). The Company paid the balance due of $378,057 under its promissory note and issued an aggregate of 160,000 shares of its restricted common stock to the two selling shareholders. In addition, the loan made by one selling shareholder in the amount of $100,000 was discharged. The amendment to the Agreement resulted in an increase of $400,000 to the purchase price of MBC, as well as the resulting goodwill in connection with the acquisition.
	Biohelath Medical Laboratory, Inc.
	On December 7, 2012, the Company, through its subsidiary, MDI, agreed to purchase 50.5% of Biohealth Medical Laboratory, Inc. ("Biohealth") from two unrelated parties for cash of $100,000 and an installment note in a total amount of $165,125.  The note was paid in $75,000 payments due on February 7 and May 7, 2013 and was reduced by a contingent consideration adjustment of $24,913, net of the final installment of $15,125 due on August 7, 2013.
	The following table summarizes the consideration given for Biohealth and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date, as well as the fair value at the acquisition date of the noncontrolling interest in Biohealth.
	Consideration Given:
	Cash	$	100,000
	Acquisition Note		165,125
	Contingent consideration adjustment		(24,913	)
	Total Consideration	$	240,212
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	19,327
	Accounts receivable		64,206
	Property and equipment, net		9,477
	Deposits		3,143
	Accounts payable		(120,590	)
	Accrued expenses		(6,110	)
	Identifiable intangible assets		275,000
Total identifiable net assets		244,453
Noncontrolling interest in Biohealth		(121,004	)
Goodwill		116,763
	$	240,212
Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
PB Laboratories, LLC
On February 16, 2012, the Company, through its subsidiary, MDI, agreed to purchase 50.5% of PB Laboratories, LLC ("PB Labs") from an unrelated party for cash of $1,000 and an installment note in a total amount of $200,000.  The note was paid in $50,000 quarterly payments over 12 months.
On October 31, 2012, MDI agreed to purchase the remaining 49.5% of PB Labs from the noncontrolling member for an installment note in a total amount of $200,000.  The note was paid in $50,000 quarterly payments over 12 months.
The following table summarizes the consideration given for PB Labs and the fair values of the assets acquired and liabilities assumed recognized at the acquisition dates of PB Labs.
Consideration Given:
Cash	$	1,000
Acquisition Notes		400,000
Total Consideration	$	401,000
Fair value of identifiable assets acquired and liabilities assumed:
Cash	$	1,876
Property and equipment, net		17,000
Identifiable intangible assets		275,000
Total identifiable net assets		293,876
Goodwill		107,124
	$	401,000
Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).

14_Commitments_and_Contingenci

14. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
14. Commitments and Contingencies	'
	Operating Lease Commitments
	The Company leases office space and business equipment for its corporate office and subsidiaries under multiple year non-cancelable operating leases that expire through 2016.  The office lease agreements have certain escalation clauses and renewal options.  Additionally, the Company has lease agreements for computer equipment, office copiers and fax machines.
	The office space lease agreements include escalating rents over the lease term. The Company expenses rent on a straight-line basis over the lease term which commences on the date the Company has the right to control the property. The cumulative expense recognized on a straight-line basis in excess of the cumulative payments is included in Accrued Expenses in the accompanying Consolidated Balance Sheets.
	At December 31, 2013, future minimum lease payments under these leases are as follows:
	Year ending December 31,
		2014	$	333,656
		2015		303,922
		2016		178,461
		2017		160,684
		2018		116,350
		2019 and thereafter		30,951
		Total minimum future lease payments	$	1,124,024
	Rent expense for the years ended December 31, 2013 and 2012 was $350,169 and $134,733, respectively.
	During the year ended December 31, 2013, the Company entered into master equipment lease agreements with a leasing company for a total commitment of up to approximately $1,400,000. As of December 31, 2013, no equipment has been delivered under the leases.
	Purchase Commitments
	The Company has entered into a purchase agreement for reagent supplies through December, 2020. Minimum purchase commitments as of December 31, 2013 are as follows:
	Year ending December 31,
		2014	$	54,871
		2015		54,871
		2016		54,871
		2017		54,871
		2018		54,871
		2019 and thereafter		109,742
		Total purchase commitments	$	384,097
	Significant Risks and Uncertainties
	[a] Concentrations of Credit Risk - Cash - At December 31, 2013 and 2012, the Company had approximately $2,631,000 and $1,070,000, respectively, in cash balances at financial institutions which were in excess of the federally insured limits.
	[b] Concentration of Credit Risk - Accounts Receivable - Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payors and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.
	A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.
	Legal Matters
	During the course of business, litigation commonly occurs.  From time to time the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry and employs personnel which may inherently lend itself to legal matters.  Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.
	On July 2, 2013, a jury awarded Medytox Institute of Laboratory Medicine, Inc., its wholly-owned subsidiary ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for defamatory postings on the internet. The jury rejected every claim made against the MILM parties. Trident's appeal has been dismissed and the appeals of the shareholders are pending.
	The case arose from the August 22, 2011 agreement among MILM and Trident and its shareholders pursuant to which MILM was to acquire 81% of Trident. On January 17, 2012, Trident notified MILM that it was rescinding the agreement. As a result, MILM filed suit against Trident and its shareholders in Florida Circuit Court in Broward County. The jury found that Trident and its shareholders breached the agreement and failed to perform their obligations thereunder.
	The Company has filed an action against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.
	On October 21, 2013, Mr. Samuels filed a complaint in the Superior Court of New Jersey (Bergen County) against the Company and Medytox Diagnostics, Inc. alleging breach of contract under his employment agreement and the agreement under which International Technologies, LLC was acquired; unjust enrichment, fraud; intentional and negligent misrepresentation; and breach of an implied duty of good faith and fair dealing and seeking an accounting. Mr. Perricelli filed a similar action. The Company believes all these claims are without merit.
	The Company removed both cases from the Superior Court of New Jersey to the federal court in the District of New Jersey. The Company also filed to transfer both cases to the Southern District of Florida pursuant to the forum selection clause in the purchase agreement. The action filed by Mr. Perricelli has since been transferred to the Southern District of Florida. The motion to transfer the action filed by Mr. Samuels remains pending.

15_Pro_Forma_Financial_Informa

15. Pro Forma Financial Information	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
15. Pro Forma Financial Information	'
	The following unaudited pro forma data summarizes the results of operations for the year ended December 31, 2013 as if the acquisitions of International Technologies, LLC had been completed January 1, 2013. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2013.
		Medytox			International Technologies,
		Solutions, Inc.			LLC			Pro Forma
		Historical			Historical			Adjustments			Ref	Combined
	Revenues	$	52,523,660		$	2,943		$	–			$	52,526,603
	Operating expenses		38,023,670			305,183			–				38,328,853
	Income (loss) from operations		14,499,990			(302,240	)		–				14,197,750
	Other income (expense)		(671,473	)		(1,343	)		–				(672,816	)
	Income (loss) before income taxes		13,828,517			(303,583	)		–				13,524,934
	Provision (benefit) for income taxes		5,568,600			–			(114,200	)	-2		5,454,400
	Net income (loss)		8,259,917			(303,583	)		114,200				8,070,534
	Preferred stock dividends		2,601,298			–			–				2,601,298
	Net income (loss) available for common shareholders	$	5,658,619		$	(303,583	)	$	114,200			$	5,469,236
	Net income per share;
	Basic and diluted	$	0.19									$	0.18
	Weighted average number of shares, basic and diluted:
	Basic and diluted		29,654,703										29,654,703
	-1	Represents unaudited results of operations of International Technologies, LLC from January 1, 2013 to April 3, 2013. International Technologies' results of operations from April 4, 2013 to December 31, 2013 are consolidated with Medytox Solutions, Inc.
	-2	Additional income tax benefit on the loss related to International Technologies for the period January 1 to April 3, 2013.

16_Subsequent_Events

16. Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
16. Subsequent Events	'
	On February 4, 2014, $235,011 of equipment was delivered under a master lease entered into during the year ended December 31, 2013. Lease terms are for 42 months with a monthly lease payment of $6,580. The lease is accounted for as a capital lease.
	On February 19, 2014, a committee of the Company’s board of directors approved the grant of 1,035,000 stock options under the Medytox Solutions, Inc. 2013 Incentive Compensation Plan to various employees. The options were granted on March 3, 2014 and were issued at an exercise price of $2.50, a term of 10 years, and 50% of the options vest each on the 6 month anniversary and 12 month anniversary of the grant date.
	On March 12, 2014, an aggregate of 210,000 shares of the Company’s restricted common stock were issued to six management executives and one consultant as partial payment of bonuses which were accrued at December 31, 2013. The shares were valued at $2.50, based on the price of shares sold to investors, for a total of $525,000.
	On March 14, 2014, an aggregate of $350,000 was paid to six management executives and one consultant as partial payment of bonuses which were accrued at December 31, 2013.
	On March 17, 2014, the Company filed a Certificate of Designation with the State of Nevada authorizing up to 200,000 shares of Series D Convertible Preferred Stock ("Series D Preferred Stock"). With respect to dividends and liquidation rights, the Series D Preferred Stock ranks (i) on a parity with the Common Stock; (ii) senior to any class or series of preferred stock of the Company created in the future not specifically ranking by its terms senior to or on a parity with the Series D Preferred Stock; (iii) junior to any other class or series of preferred stock created in the future specifically ranking by its terms senior to the Series D Preferred Stock; and (iv) on a parity with the Series B Preferred Stock and any other class or series of preferred stock created in the future specifically ranking by its terms on a parity with the Series D Preferred Stock.
	On March 18, 2014, MDI, pursuant to a stock purchase agreement, purchased all of the outstanding stock of Clinlab, Inc. ("Clinlab") from James A. Wilson and Daniel Stewart, previously the sole owners of Clinlab. Clinlab develops and markets laboratory information management systems. The purchase price was an aggregate of $2,250,000, $1,000,000 in cash and 200,000 shares of Series D Convertible Preferred Stock of the Company, convertible into $1,250,000 of common stock of the Company at the date of conversion.
	On March 27, 2014, TCA Global Credit Master Fund, LP extended the maturity date of its loan to the Company until September 15, 2014.
	On March 28, 2014, Sebastien Sainsbury was appointed to the Board of Directors of the Company.
	Each of the holders of shares of Series B Preferred Stock, Epizon, Ltd., of which Seamus Lagan is the sole shareholder, Aella, Ltd., of which Sharon L. Hollis is the sole shareholder, Francisco Roca, III, Dr. Thomas F. Mendolia and Steven Sramowicz, entered into a purchase option agreement with the Company as of March 27, 2014. Each agreement grants the Company an option to purchase any or all shares of Series B Preferred Stock held by the holder at any time through March 27, 2016. Each holder owns 1,000 shares of Series B Preferred Stock. If all of a holder's shares are purchased by the Company pursuant to the option, the purchase price would be $5,000,000. If fewer shares are purchased from a holder, the purchase price would be adjusted proportionately. Each holder agreed not to transfer or dispose of any shares of Series B Preferred Stock during the term of the option, other than to the Company upon an exercise of the option. Any exercise of an option is completely at the Company's discretion.
	The Company has evaluated subsequent events through the date the financial statements were issued and filed with SEC. The Company has determined that there are no other events that warrant disclosure or recognition in the financial statements.

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization	'
	Medytox Solutions, Inc. (the “Company”), was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On June 22, 2011, the Company organized Medytox Medical Management Solutions Corp. ("MMMSC"), a Florida corporation, as a wholly-owned subsidiary.  MMMSC was a marketing company selling laboratory testing services to medical clinics, hospitals and physicians’ offices.   On October 15, 2013, MMMSC changed its name to Medytox Information Technology, Inc. (“MIT”). MIT provides information technology services and solutions to all subsidiaries and customers of the Company and operates from the corporate offices in West Palm Beach, Florida.
	On July 26, 2011, the Company organized Medytox Institute of Laboratory Medicine, Inc. ("MILM"), a Florida corporation, as a wholly-owned subsidiary.  MILM was organized to acquire and manage medical testing laboratories.  MILM operates from the corporate offices in West Palm Beach, Florida.
	On August 22, 2011, the Company acquired 100% of Medical Billing Choices, Inc. ("MBC"), a privately-owned North Carolina corporation, through a stock purchase agreement for cash and an installment note.  MBC operates a medical billing service for a variety of medical providers throughout the southeastern United States from offices in Charlotte, North Carolina.  Since the acquisition, MBC is the main billing company for the Company's laboratories.
	On February 6, 2012, the Company formed Medytox Diagnostics Inc. (“MDI”), a Florida corporation, as a wholly-owned subsidiary to acquire and build clinical laboratories. MDI operates from the corporate offices in West Palm Beach, Florida.
	On February 16, 2012, MDI acquired majority interest in Collectaway LLC, now known as PB Laboratories, LLC ("PB Labs"), a Florida limited liability company.   On October 31, 2012, MDI acquired the remaining noncontrolling interest in PB Labs.  As of October 31, 2012, PB Labs is a wholly-owned subsidiary of MDI.
	On December 7, 2012, MDI acquired a majority interest in Biohealth Medical Laboratory, Inc. (“Biohealth”), a Florida corporation.
	On January 1, 2013, MDI purchased 100% of the stock of Alethea Laboratories, Inc. ("Alethea").  Althea operates a licensed clinical lab in Las Cruces, New Mexico and is an enrolled Medicare provider.
	On January 29, 2013, MDI formed Advantage Reference Labs, Inc. (“Advantage”), a Florida corporation, as a wholly-owned subsidiary that will provide reference, confirmation and clinical testing services. On October 14, 2013, Advantage changed its name to EPIC Reference Labs, Inc. (“EPIC”).
	On March 9, 2013, the Company formed Medytox Medical Marketing & Sales, Inc. (“MMMS”), a Florida corporation, as a wholly-owned subsidiary that provides marketing for clinical laboratories that are owned by the Company.
	On April 4, 2013, MDI purchased 100% of the interests in International Technologies, LLC ("Tech").  In October 2013, Tech began doing business as NJ Reference labs (“NJ Ref”). NJ Ref operates a licensed clinical lab in Waldwick, New Jersey and is an enrolled Medicare provider.
Nature of Operations	'
	The Company operates in the medical services segment.
Basis of Presentation	'
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”).
Reclassifications	'
	Certain items on the statement of operations for the year ended December 31, 2012 have been reclassified to conform to the current period presentation.
Use of Estimates	'
	The preparation of financial statements in conformity with generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant areas of estimate include the impairment of assets and rates for amortization, accrued liabilities, future income tax obligations and the inputs used in calculating stock-based compensation and transactions. Actual results could differ from those estimates and would impact future results of operations and cash flows.
Principles of Consolidation	'
	The consolidated financial statements include the accounts of Medytox Solutions, Inc. and its wholly-owned subsidiaries, Medytox Information Technology, Inc., Medytox Institute of Laboratory Medicine, Inc., Medical Billing Choices, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Medytox Medical Marketing & Sales, Inc., Alethea Laboratories, Inc., EPIC Reference Labs, Inc., and International Technologies, LLC, and its majority-owned subsidiary, Biohealth Medical Laboratory, Inc.  Due to the dispute with Trident and its selling shareholders (see Note – 4), the accounts of Trident Laboratories, Inc. have been excluded from consolidation.  In addition, a disputed net income reserve of $397,918 has been established as of December 31, 2012 representing all of Trident’s net income recognized by the Company since August 22, 2011, the date of acquisition.  All significant inter-company balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	'
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2013 and 2012, respectively, the Company had no cash equivalents.
Revenue Recognition	'
	Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis and urine analysis. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.
	Net service revenues are determined utilizing gross service revenues net of contractual allowances. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Medytox are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information. We estimate that 0% of self-pay billings will be collectible. The Company currently does not have any capitated agreements. In the remainder of the cases, Medytox is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like Medytox. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends.
	We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. Bad debt expense represents our estimate of net revenues that will ultimately be uncollectable and is based upon our analysis of historical payment rates by specific payor groups on a monthly basis with primary weight being given to the most recent trends; this approach allows bad debt to more accurately adjust to short-term changes in the business environment. These two calculations are routinely analyzed by Medytox on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.
Contractual Allowances and Doubtful Accounts Policy	'
	Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectibility of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectibility of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense within selling, general and administrative expenses. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.
	As of December 31, 2013 and 2012, management recorded allowances for uncollectible accounts in the amount of $3,621,814 and $1,297,769, respectively.  Bad debt expense was $10,634,789 and $7,021,945 for the years ended December 31, 2013 and 2012, respectively.
Impairment or Disposal of Long-Lived Assets	'
	The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.  The Company did not recognize any impairment losses for the years ended December 31, 2013 and 2012.
Fair Value of Financial Instruments	'
	The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.
	ASC 820 “Fair Value Measurements and Disclosures” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) a reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means; and
	Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013 and 2012. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.
	The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.
	As of December 31, 2013 and 2012 the fair values of the Company’s financial instruments approximate their historical carrying amount.
Advertising	'
	The costs of advertising are expensed as incurred.  Advertising expense was $21,550 and $111,691 for the years ended December 31, 2013 and 2012, respectively.  Advertising expenses are included in the Company’s operating expenses.
Stock Based Compensation	'
	The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in stockholders' equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.
	The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.
Income Taxes	'
	Income taxes are accounted for under the liability method of accounting for income taxes.  Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.  Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled.  The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs.  Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.
	The FASB has issued ASC 740 “Income Taxes”.  ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements.  This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.
	As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of December 31, 2013.
Basic and Diluted Income Per Share	'
	The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations.  Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period.  Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method.  In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.  Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.  As of December 31, 2013, there were a total of 23,170,000 stock options outstanding to purchase shares of common stock, 346,400 warrants outstanding to purchase shares of common stock, a $100,000 convertible debenture convertible into 40,000 shares of the Company’s common stock, and $500,000 of convertible notes payable convertible into shares of the Company’s common stock at a 10% discount to the average market price for the thirty days prior to conversion.  However, these potentially dilutive shares are considered to be anti-dilutive and are therefore not included in the calculation of income per share.
Segment Information	'
	In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of December 31, 2013 and 2012.

4_Disputed_Subsidiary_Tables

4. Disputed Subsidiary (Tables)	12 Months Ended
	Dec. 31, 2013
Disputed Subsidiary Tables	'
Assets and liabilities of the subsidiary	'
	Assets and liabilities of the disputed subsidiary as of December 31, 2013 and 2012 were as follows:
	Total assets	$	1,367,796
	Total liabilities	$	1,104,063

5_LongLived_Assets_Tables

5. Long-Lived Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and equipment	'
	Property and equipment at December 31, 2013 and 2012 consisted of the following:
		December 31,
		2013			2012
	Medical equipment	$	655,125		$	269,931
	Equipment		111,265			37,140
	Equipment under capital leases		980,948			–
	Furniture		206,587			66,606
	Leasehold improvements		243,983			47,197
	Vehicles		177,534			70,828
	Computer equipment		235,507			85,478
	Software		285,175			196,711
			2,896,124			773,891
	Less accumulated depreciation		(739,743	)		(175,150	)
	Property and equipment, net	$	2,156,381		$	598,741

6_Accrued_Expenses_Tables

6. Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued expenses	'
	Accrued expenses at December 31, 2013 and 2012 consisted of the following:
		December 31,
		2013		2012
	Commissions payable	$	277,731	$	–
	Dividends payable		360,726		–
	Accrued payroll and related liabilities		114,471		283,490
	Accrued bonuses		1,900,000		500,000
	Accrued interest		46,842		146,943
	Other accrued expenses		156,114		96,489
	Accrued expenses	$	2,855,884	$	1,026,922

7_Notes_Payable_Tables

7. Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Notes Payable	'
	The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties.  At December 31, 2013 and 2012, notes payable consisted of the following:
		December 31,
		2013			2012
	Convertible debenture for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%.  Interest only payments are payable monthly.  The note is convertible at $2.50 per share. The due date of the note was extended from October 31, 2013 to February 5, 2014 by the lender.  This note is subordinated to the loan from TCA Global Credit Master Fund, L.P. ("TCA") and is secured by the assets of the Company, Medytox Information Technology Inc. ("MIT") and Trident.	$	100,000		$	500,000
	Loan for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%.  Interest and principal was payable in 10 equal payments ending August 31, 2013.  This note was subordinated to the loan from TCA and was secured by the assets of the Company, MIT and Trident.		–			150,000
	Acquisition note to former shareholders of Medical Billing Choices, Inc. ("MBC") in the amount of $750,000, with interest at 6%, payable by August 22, 2013.		–			449,512
	Loan from TCA.  Principal of $2,475,000 and $1,725,000, respectively, payable by January 15, 2014.  The note was extended from January 15, 2014 to September 15, 2014, and is secured by all assets of the Company and its subsidiaries (other than Trident and MBC).  See "TCA Global" below.		2,475,000			1,725,000
	Acquisition note to former member of PB Laboratories, LLC for 50.5% ownership, in the amount of $200,000 at 6% interest, with payments of $50,000 quarterly starting May 17, 2012.		–			50,000
		December 31,
		2013			2012
	Acquisition note to former member of PB Laboratories, LLC for 49.5% ownership, in the amount of $200,000 at 0% interest, with payments of $50,000 quarterly starting January 31, 2013.		–			150,000
	Acquisition note to former shareholder of Biohealth Medical Laboratory, Inc. for 50.5% ownership, in the amount of $165,125 at 0% interest, with payments of $75,000 due quarterly starting February 7, 2013 and a final payment of $15,125 due on August 7, 2013.  In May 2013, a final settlement was reached with the former shareholder and the remaining balance of $24,677 as of May 31, 2013 was discharged.		–			99,677
	Short-term note from affiliate, non-interest bearing and is due on demand.		–			30,200
	Acquisition note No.1 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		150,000			–
	Acquisition note No. 2 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		150,000			–
	Loan from former shareholders of Alethea Laboratories, Inc. in the amount of $344,650 at 4% interest, with principal payments of $24,618 due monthly starting March 15, 2013.		98,471			–
	Commercial loan with a finance company, dated December 20, 2012, in the original amount of $18,249 and bearing interest at 12.59%.  Principal and interest payments in the amount of $364 are payable for 72 months ending on January 3, 2019. This note is secured by a lien on a vehicle with a carrying value of $16,623 at December 31, 2013.		15,845			–
	Commercial loan with a finance company, dated November 15, 2012, in the original amount of $18,008 and bearing interest at 15.07%.  Principal and interest payments in the amount of $384 are payable for 72 months ending on November 30, 2018. This note is secured by a lien on a vehicle with a carrying value of $16,430 at December 31, 2013.		16,279			–
	Commercial loan with a finance company, dated November 28, 2012, in the original amount of $20,345 and bearing interest at 8.99%.  Principal and interest payments in the amount of $368 are payable for 72 months ending on January 12, 2019. This note is secured by a lien on a vehicle with a carrying value of $18,300 at December 31, 2013.		17,676			–
		December 31,
		2013			2012
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest, due January 17, 2014.  The note is convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $1,639 at December 31, 2013.		248,361			–
	Acquisition convertible note No. 2 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest, due January 17, 2014.  The note is convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $1,639 at December 31, 2013.		248,361			–
	Loan from former member of International Technologies, LLC in the remaining amount of $416,667 at the date of acquisition, at 1% interest, with principal payments of $83,333 due quarterly starting June 7, 2013.		166,668			–
	Loan from former member of International Technologies, LLC in the remaining amount of $112,500 at the date of acquisition, at 1% interest, with principal payments of $22,500 due quarterly starting June 7, 2013.		45,000			–
			3,731,661			3,154,389
	Less current portion		(3,689,554	)		(3,154,389	)
	Notes payable, net of current portion	$	42,107		$	–
Deferred loan costs	'
	The Company has incurred certain loan costs as inducement for loans and has recorded them as deferred loan costs.  The loan costs are amortized as interest expense on a straight-line basis over the life of the loan. Deferred loan costs at December 30, 2013 and 2012 consisted of the following:
		December 31,
		2013			2012
	Deferred loan costs	$	425,899		$	321,950
	Less accumulated accretion as interest		(425,899	)		(244,758	)

9_Capital_Lease_Obligations_Ta

9. Capital Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2013
Capital Lease Obligations [Abstract]	'
Capital leased assets	'
		December 31,
		2013				2012
	Medical equipment	$	980,948			$	–
	Less accumulated depreciation		(364,726	)			–
	Net	$	616,222			$	–
Aggregate future minimum rentals under capital leases	'
	December 31,
	2014			$	203,865
	2015				208,612
	2016				82,058
	2017				35,575
	2018				35,575
	Thereafter				68,186
	Total				633,871
	Less interest:				35,058
	Present value of minimum lease payments				598,813
	Less current portion of capital lease obligations				193,095
	Capital lease obligations, net of current portion			$	405,718

11_Stockholders_Equity_Tables

11. Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Options outstanding	'
	The following summarizes option activity for the years ended December 31, 2013 and 2012:
															Weighted
			Common Stock Options Outstanding												average
			Employees and												exercise
			Directors				Non-employees				Total				price
	Outstanding at December 31, 2011			–				400,000				400,000				4.5
	Options granted			19,300,000				3,020,000				22,320,000			$	5.66
	Options exercised			–				–				–				–
	Options cancelled or expired			(1,000,000	)			(400,000	)			(1,400,000	)			3.43
	Outstanding at December 31, 2012			18,300,000				3,020,000				21,320,000				5.79
	Options granted			1,850,000				–				1,850,000				3.24
	Options exercised			–				–				–				–
	Options cancelled or expired			–				–				–				–
	Balance at December 31, 2013			20,150,000				3,020,000				23,170,000			$	5.33
Schedule of stock option activity	'
	The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at September 30, 2013:
					Options outstanding														Options vested and exercisable
									Weighted
									average				Weighted								Weighted
									remaining				average				Aggregate				average		Aggregate
					Number				contractual				exercise				intrinsic			Number	exercise		intrinsic
	Exercise price				outstanding				life (years)				price				value			vested	price		value
	$	2.5				7,550,000				3.66			$	2.5			$	–		7,450,000	$	2.5	$	–
	$	5				6,600,000				3.97			$	5				–		6,500,000	$	5		–
	$	10				6,000,000				9.01			$	10				–		6,000,000	$	10		–
						20,150,000							$	5.55			$	–		19,950,000	$	5.57	$	–
	The following table summarizes information with respect to stock options outstanding and exercisable by non-employees at December 31, 2013:
					Options outstanding														Options vested and exercisable
									Weighted
									average				Weighted								Weighted
									remaining				average				Aggregate				average		Aggregate
					Number				contractual				exercise				intrinsic			Number	exercise		intrinsic
	Exercise price				outstanding				life (years)				price				value			vested	price		value
	$	2.5				1,020,000				3.94			$	2.5			$	–		1,020,000	$	2.5	$	–
	$	5				1,000,000				4			$	5				–		1,000,000	$	5		–
	$	10				1,000,000				9.01			$	10				–		1,000,000	$	10		–
						3,020,000							$	5.81			$	–		3,020,000	$	5.81	$	–
Option assumptions	'
	The Company estimated the fair value of employee stock options using the Black-Scholes Option Pricing Model. The fair value of employee stock options is expensed upon vesting of the awards. The fair value of employee stock options was estimated using the following assumptions:
	Stock price	$0.00
	Expected term	1 to 5 years
	Expected volatility	29 to 30%
	Risk-free interest rate	0.25 to 0.72%
	Dividend yield	0
	During the year ended December 31, 2013, the Company issued options to purchase a total of 600,000 shares of the Company’s common stock to two directors. These options have contractual lives of four years and were valued at an average grant date fair value of $0.20 per option, or $120,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Contractual term	4 years
	Expected volatility	26.48%
	Risk free interest rate	0.54%
	Dividend yield	0
	During the year ended December 31, 2013, the Company issued options to purchase a total of 1,250,000 shares of the Company’s common stock to an employee. These options have contractual lives of three to five years and were valued at an average grant date fair value of $0.30 per option, or $372,500, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Contractual term	3 to 5 years
	Expected volatility	29.50%
	Risk free interest rate	0.32% to 0.47%
	Dividend yield	0
	The Company estimated the fair value of non-employee stock options using the Black-Scholes Option Pricing Model. The fair value of employee stock options is expensed upon vesting of the awards. The fair value of non-employee stock options was estimated using the following assumptions:
	Stock price	$0.00
	Expected term	2 to 10 years
	Expected volatility	29 - 30%
	Risk-free interest rate	0.25 – 1.78%%
	Dividend yield	0
Warrant transactions	'
	The following table summarizes warrant transactions for the year ended December 31, 2013:
											Weighted
							Weighted				average
							average				remaining				Aggregate
			Number				exercise				contractual				intrinsic
			of warrants				price				term (years)				value
	Outstanding at December 31, 2012			–			$	–							$	–
	Granted in 2013			346,400			$	3.22
	Outstanding at December 31, 2013			346,400			$	3.22				0.94			$	–
	Exercisable at December 31, 2013			346,400			$	3.22				0.94			$	–
	Weighted Average Grant Date Fair Value						$	0.25
Warrant assumption	'
	During the year ended December 31, 2013, the Company issued warrants to purchase a total of 46,400 shares of the Company’s common stock in conjunction with sales of Units. These warrants have contractual lives of one year and were valued at a grant date fair value of $-0- per warrant using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$0.01
	Contractual term	1 year
	Expected volatility	29.13%
	Risk free interest rate	0.15%
	Dividend yield	0
	During the year ended December 31, 2013, the Company issued warrants to purchase a total of 300,000 shares of the Company’s common stock to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants have contractual lives of two years and were valued at an average grant date fair value of $0.283 per warrant, or $85,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Contractual term	2 years
	Expected volatility	29.13%
	Risk free interest rate	0.27%
	Dividend yield	0

12_Income_Taxes_Tables

12. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes Tables	'
Iincome tax provision are summarized	'
	Significant components of the income tax provision are summarized as follows:
		Year Ended December 31,
		2013			2012
	Current provision:
	Federal	$	5,834,600		$	1,702,200
	State		1,027,500			181,700
	Deferred provision:
	Federal		(1,168,700	)		(1,267,200	)
	State		(124,800	)		(135,300	)
		$	5,568,600		$	481,400
Statutory federal income tax rate to the Company's effective income tax rate on income before income taxes	'
	A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate on income before income taxes for the years ended December 31, 2013 and 2012 is as follows:
		Year Ended December 31,
		2013			2012
	Expected federal income tax at 34% statutory rate		34.00%			34.00%
	State income taxes		4.30%			3.60%
	Permanent differences		2.00%			3.50%
	Change in valuation allowance		0.00%			-26.00%
			40.30%			15.10%
Deferred tax assets and liabilities are comprised	'
	The Company provides for income taxes using the liability method in accordance with FASB ASC Topic 740 “Income Taxes”. Deferred income taxes arise from the differences in the recognition of income and expenses for tax purposes. Deferred tax assets and liabilities are comprised of the following at December 31, 2013 and 2012:
		December 31,
		2013			2012
	Deferred income tax assets:
	Allowance for bad debts	$	1,362,900		$	1,980,600
	Accrued compensation		385,700			–
	Stock options		170,300			–
	Total deferred income tax assets	$	1,918,900		$	1,980,600
	Deferred income tax liabilities:
	Property and equipment	$	(76,100	)	$	–
	Intangible amortization		(136,000	)		(36,100	)
	Total deferred income tax liabilities	$	(212,100	)	$	(36,100	)
	Net deferred income taxes:
	Current		1,748,600			1,980,600
	Non-current		(41,800	)		(36,100	)
		$	1,706,800		$	1,944,500

13_Business_Combinations_Table

13. Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of goodwill	'
	Goodwill was attributable to the following subsidiaries as of December 31, 2013 and December 31, 2012:
		December 31,
		2013			2012
	Medical Billing Choices, Inc.	$	1,202,112		$	802,112
	PB Laboratories, LLC		107,124			107,124
	Biohealth Medical Laboratory, Inc.		116,763			141,676
		$	1,425,999		$	1,050,912
Consideration given	'
	The following table summarizes the consideration given for Intl Tech and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date.
	Consideration Given:
	Cash	$	127,000
	Amount due from International Technologies, LLC		483,052
	Acquisition notes		500,000
	Total Consideration	$	1,110,052
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	1,703
	Property and equipment, net		31,649
	Accounts payable and accrued expenses		(59,462	)
	Notes payable		(529,167	)
	Identified intangible assets		1,665,329
	Total identifiable net assets		1,110,052
	Goodwill and unidentified intangible assets		–
		$	1,110,052
	Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
	Alethea Laboratories, Inc.
	On January 1, 2013, the Company, through its subsidiary, MDI, agreed to purchase 100% of Alethea Laboratories, Inc. ("Alethea") from two unrelated parties for cash of $125,000 and two non-interest bearing installment notes in a total amount of $575,000.  The notes are being paid in $50,000 quarterly installments beginning on April 1, 2013.
	The following table summarizes the consideration given for Alethea and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date.
	Consideration Given:
	Cash	$	125,000
	Acquisition notes		575,000
	Total Consideration	$	700,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	2,032
	Property and equipment, net		92,498
	Capital lease assets, net		392,817
	Accounts payable		(2,032	)
	Note payable		(344,650	)
	Capital lease obligation		(415,949	)
	Identified intangible assets		975,284
	Total identifiable net assets		700,000
	Goodwill and unidentified intangible assets		–
		$	700,000
	Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
	Medical Billing Choices, Inc.
	On July 12, 2013, the Company and the two selling shareholders amended the Agreement, dated August 22, 2011, pursuant to which the Company had acquired Medical Billing Choices, Inc. (“MBC”). The Company paid the balance due of $378,057 under its promissory note and issued an aggregate of 160,000 shares of its restricted common stock to the two selling shareholders. In addition, the loan made by one selling shareholder in the amount of $100,000 was discharged. The amendment to the Agreement resulted in an increase of $400,000 to the purchase price of MBC, as well as the resulting goodwill in connection with the acquisition.
	Biohelath Medical Laboratory, Inc.
	On December 7, 2012, the Company, through its subsidiary, MDI, agreed to purchase 50.5% of Biohealth Medical Laboratory, Inc. ("Biohealth") from two unrelated parties for cash of $100,000 and an installment note in a total amount of $165,125.  The note was paid in $75,000 payments due on February 7 and May 7, 2013 and was reduced by a contingent consideration adjustment of $24,913, net of the final installment of $15,125 due on August 7, 2013.
	The following table summarizes the consideration given for Biohealth and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date, as well as the fair value at the acquisition date of the noncontrolling interest in Biohealth.
	Consideration Given:
	Cash	$	100,000
	Acquisition Note		165,125
	Contingent consideration adjustment		(24,913	)
	Total Consideration	$	240,212
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	19,327
	Accounts receivable		64,206
	Property and equipment, net		9,477
	Deposits		3,143
	Accounts payable		(120,590	)
	Accrued expenses		(6,110	)
	Identifiable intangible assets		275,000
	Total identifiable net assets		244,453
	Noncontrolling interest in Biohealth		(121,004	)
	Goodwill		116,763
		$	240,212
	Intangible assets consisting of certain medical licenses were valued by management based on the fair value of obtaining such licenses.  As the licenses have indefinite lives, the intangible assets are non-amortizable (See Note 5 – Long-Lived Assets).
	PB Laboratories, LLC
	On February 16, 2012, the Company, through its subsidiary, MDI, agreed to purchase 50.5% of PB Laboratories, LLC ("PB Labs") from an unrelated party for cash of $1,000 and an installment note in a total amount of $200,000.  The note was paid in $50,000 quarterly payments over 12 months.
	On October 31, 2012, MDI agreed to purchase the remaining 49.5% of PB Labs from the noncontrolling member for an installment note in a total amount of $200,000.  The note was paid in $50,000 quarterly payments over 12 months.
	The following table summarizes the consideration given for PB Labs and the fair values of the assets acquired and liabilities assumed recognized at the acquisition dates of PB Labs.
	Consideration Given:
Cash	$	1,000
Acquisition Notes		400,000
Total Consideration	$	401,000
Fair value of identifiable assets acquired and liabilities assumed:
Cash	$	1,876
Property and equipment, net		17,000
Identifiable intangible assets		275,000
Total identifiable net assets		293,876
Goodwill		107,124
	$	401,000

14_Commitments_and_Contingenci1

14. Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Tables	'
Future minimum operating lease payments	'
	Year ending December 31,
		2014	$	333,656
		2015		303,922
		2016		178,461
		2017		160,684
		2018		116,350
		2019 and thereafter		30,951
		Total minimum future lease payments	$	1,124,024
Minimum purchase commitments	'
	The Company has entered into a purchase agreement for reagent supplies through December, 2020. Minimum purchase commitments as of December 31, 2013 are as follows:
	Year ending December 31,
		2014	$	54,871
		2015		54,871
		2016		54,871
		2017		54,871
		2018		54,871
		2019 and thereafter		109,742
		Total purchase commitments	$	384,097

15_Pro_Forma_Financial_Informa1

15. Pro Forma Financial Information (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Pro forma financial information	'
	summarizes the results of operations for the year ended December 31, 2013 as if the acquisitions of International Technologies, LLC had been completed January 1, 2013. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2013.
		Medytox			International Technologies,
		Solutions, Inc.			LLC			Pro Forma
		Historical			Historical			Adjustments			Ref	Combined
	Revenues	$	52,523,660		$	2,943		$	–			$	52,526,603
	Operating expenses		38,023,670			305,183			–				38,328,853
	Income (loss) from operations		14,499,990			(302,240	)		–				14,197,750
	Other income (expense)		(671,473	)		(1,343	)		–				(672,816	)
	Income (loss) before income taxes		13,828,517			(303,583	)		–				13,524,934
	Provision (benefit) for income taxes		5,568,600			–			(114,200	)	-2		5,454,400
	Net income (loss)		8,259,917			(303,583	)		114,200				8,070,534
	Preferred stock dividends		2,601,298			–			–				2,601,298
	Net income (loss) available for common shareholders	$	5,658,619		$	(303,583	)	$	114,200			$	5,469,236
	Net income per share;
	Basic and diluted	$	0.19									$	0.18
	Weighted average number of shares, basic and diluted:
	Basic and diluted		29,654,703										29,654,703
	-1	Represents unaudited results of operations of International Technologies, LLC from January 1, 2013 to April 3, 2013. International Technologies' results of operations from April 4, 2013 to December 31, 2013 are consolidated with Medytox Solutions, Inc.
	-2	Additional income tax benefit on the loss related to International Technologies for the period January 1 to April 3, 2013.

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Allowances for uncollectible accounts	$3,621,814	$1,297,769
Bad debt expense	10,634,789	7,021,945
Advertising expense	$21,550	$111,691
Stock Options	'	'
Antidilutive shares excluded from EPS	23,170,000	'
Warrants	'	'
Antidilutive shares excluded from EPS	346,400	'
Convertible Debentures	'	'
Antidilutive shares excluded from EPS	40,000	'

4_Disputed_Subsidiary_Details

4. Disputed Subsidiary (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Assets of disupted subsidiary	$1,367,796	$1,367,796
Liabilities of disputed subsidiary	1,104,063	1,104,063
Disputed Subsidiary	'	'
Assets of disupted subsidiary	1,367,796	1,367,796
Liabilities of disputed subsidiary	$1,104,063	$1,104,063

4_Disputed_Subsidiary_Details_

4. Disputed Subsidiary (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Legal fees	$976,789	$325,762
Disputed net income - Trident	397,918	397,918
Disputed Subsidiary	'	'
Legal fees	976,789	325,762
Disputed net income - Trident	'	397,918
Commissions payable	$389,135	$389,135

5_LongLived_Assets_Details

5. Long-Lived Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property and equipment, gross	$2,896,124	$773,891
Accumulated depreciation	-739,743	-175,150
Property and equipment, net	2,156,381	598,741
Medical equipment	'	'
Property and equipment, gross	655,125	269,931
Equipment	'	'
Property and equipment, gross	111,265	37,140
Capital lease assets	'	'
Property and equipment, gross	980,948	0
Furniture	'	'
Property and equipment, gross	206,587	66,606
Leasehold Improvements	'	'
Property and equipment, gross	243,983	47,197
Vehicles	'	'
Property and equipment, gross	177,534	70,828
Computer Equipment	'	'
Property and equipment, gross	235,507	85,478
Software	'	'
Property and equipment, gross	$285,175	$196,711

5_LongLived_Assets_Details_Nar

5. Long-Lived Assets (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$407,971	$65,648
Medical licenses	$3,190,613	$550,000

6_Accrued_Expenses_Details

6. Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued expenses	$2,855,884	$1,026,922
Disputed Subsidiary	'	'
Commissions payable	277,731	0
Dividends payable	360,726	0
Accrued payroll and related liabilities	114,471	283,490
Accrued bonuses	1,900,000	500,000
Accrued interest	46,842	146,943
Other accrued expenses	156,114	96,489
Accrued expenses	$2,855,884	$1,026,922

7_Notes_Payable_DetailsNotes_P

7. Notes Payable (Details-Notes Payable) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Notes payable, total	$3,731,661	$3,154,389
Less: current portion	-3,689,554	-3,154,389
Notes payable, net of current portion	42,107	0
Convertible debenture for working capital	'	'
Notes payable, total	100,000	500,000
Loan for working capital	'	'
Notes payable, total	0	150,000
Acquisition note to MBC shareholders	'	'
Notes payable, total	0	449,512
Loan from TCA	'	'
Notes payable, total	2,475,000	1,725,000
Acquisition note to former member of PB	'	'
Notes payable, total	0	50,000
Acquisition note to fomer member of PB	'	'
Notes payable, total	0	150,000
Acquisition note to fomer member of Biohealth	'	'
Notes payable, total	0	99,677
Short-term note	'	'
Notes payable, total	0	30,200
Acquisition note 1 to Alethea	'	'
Notes payable, total	150,000	0
Acquisition note 2 to Alethea	'	'
Notes payable, total	150,000	0
Loan to former shareholders Alethea	'	'
Notes payable, total	98,471	0
Commercial loan	'	'
Notes payable, total	15,845	0
Commercial loan 2	'	'
Notes payable, total	16,279	0
Commercial loan 3	'	'
Notes payable, total	17,676	0
Acquisition convertible note 1	'	'
Notes payable, total	248,361	0
Acquisition convertible note 2	'	'
Notes payable, total	248,361	0
Loan from former member Intl Technologies	'	'
Notes payable, total	166,668	0
Loan 2 from former member Intl Technologies	'	'
Notes payable, total	$45,000	$0

7_Notes_Payable_DetailsDeferre

7. Notes Payable (Details-Deferred loan costs) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'
Deferred loan costs	$425,899	$321,950
Less: accumulated accretion as interest	-425,899	-244,758
Deferred loan costs, net	$0	$77,192

8_Related_Party_Transactions_D

8. Related Party Transactions (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Forhan	'	'
Outstanding to related parties	'	$57,100
Payments made to related parties	10,000	'
Capital contribution	47,100	'
Alcimede	'	'
Outstanding to related parties	'	85,000
Payments made to related parties	85,000	'
Payments made pursuant to consulting agreement	240,000	240,000
Payments made for certain operating expenses and asset purchases	520,334	71,422
Interest paid	18,417	'
DASH	'	'
Payments made pursuant to consulting agreement	33,070	116,930
MBC Shareholder	'	'
Outstanding to related parties	'	100,000
Mendolia	'	'
Payments made for certain operating expenses and asset purchases	$252,841	$48,786

9_Capital_Lease_Obligations_De

9. Capital Lease Obligations (Details-Capital leased assets) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Capital Lease Obligations [Abstract]	'	'
Medical equipment	$980,948	$0
Less accumulated depreciation	-364,726	0
Net	$616,222	$0

9_Capital_Lease_Obligations_De1

9. Capital Lease Obligations (Details-Future miminum rentals) (USD $)	Dec. 31, 2013
Capital Lease Obligations [Abstract]	'
2014	$203,865
2015	208,612
2016	82,058
2017	35,575
2018	35,575
Thereafter	68,186
Total	633,871
Less interest:	35,058
Present value of minimum lease payments	598,813
Less current portion of capital lease obligations	193,095
Capital lease obligations, net of current portion	$405,718

9_Capital_Lease_Obligations_De2

9. Capital Lease Obligations (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013
Capital Lease Obligations [Abstract]	'
Depreciation expense	$137,306

10_Stockholders_Equity_Details

10. Stockholders' Equity (Details-Option Activity) (Stock Options, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Options outstanding	'	'
Options outstanding, beginning balance	21,320,000	400,000
Options granted	1,850,000	22,320,000
Options exercised	'	'
Options cancelled or expired	'	-1,400,000
Options outstanding, ending balance	23,170,000	21,320,000
Weighted Average Exercise Price	'	'
Options outstanding, beginning balance	$5.79	$4.50
Options granted	$3.24	$5.66
Options exercised	'	'
Options cancelled or expired	'	$3.43
Options outstanding, ending balance	$5.33	$5.79
Employees and Directors	'	'
Options outstanding	'	'
Options outstanding, beginning balance	18,300,000	0
Options granted	1,850,000	19,300,000
Options exercised	'	'
Options cancelled or expired	'	-1,000,000
Options outstanding, ending balance	20,150,000	18,300,000
Weighted Average Exercise Price	'	'
Options outstanding, ending balance	$5.55	'
Non-Employee	'	'
Options outstanding	'	'
Options outstanding, beginning balance	3,020,000	400,000
Options granted	'	3,020,000
Options exercised	'	'
Options cancelled or expired	'	-400,000
Options outstanding, ending balance	3,020,000	3,020,000

10_Stockholders_Equity_Details1

10. Stockholders' Equity (Details-Options outstanding and exercisable) (Stock Options, USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				Employees and Directors	Employees and Directors	Employees and Directors	Exercise price $2.50	Exercise price $5.00	Exercise price $10.00
							Employees and Directors	Employees and Directors	Employees and Directors
Options Outstanding - Employees and Directors	'	'	'	'	'	'	'	'	'
Options outstanding	23,170,000	21,320,000	400,000	20,150,000	18,300,000	0	7,550,000	6,600,000	6,000,000
Weighted average remaining contractual life	'	'	'	'	'	'	'3 years 7 months 28 days	'3 years 11 months 19 days	'9 years 4 days
Weighted average exercise price - outstanding	$5.33	$5.79	$4.50	$5.55	'	'	$2.50	$5	$10
Aggregate intrinsic value - outstanding	'	'	'	$0	'	'	$0	$0	$0
Options Vested and Exercisable - Employees and Directors	'	'	'	'	'	'	'	'	'
Options vested	'	'	'	19,950,000	'	'	7,450,000	6,500,000	6,000,000
Weighted average exercise price - vested and exercisable	'	'	'	$5.55	'	'	$2.50	$5	$10
Aggregate intrinsic value - vested and exercisable	'	'	'	$0	'	'	$0	$0	$0

10_Stockholders_Equity_Details2

10. Stockholders' Equity (Details-Non-employee options outstanding) (Stock Options, USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				Non-Employee	Exercise price $2.50	Exercise price $5.00	Exercise price $10.00
					Non-Employee	Non-Employee	Non-Employee
Options Outstanding - Non-Employees	'	'	'	'	'	'	'
Options outstanding	23,170,000	21,320,000	400,000	3,020,000	1,020,000	1,000,000	1,000,000
Weighted average remaining contractual life	'	'	'	'	'3 years 11 months 9 days	'4 years	'9 years 4 days
Weighted average exercise price - outstanding	$5.33	$5.79	$4.50	$5.81	$2.50	$5	$10
Aggregate intrinsic value - outstanding	'	'	'	$0	$0	$0	$0
Options Vested and Exercisable - Non-Employees	'	'	'	'	'	'	'
Options vested	'	'	'	3,020,000	1,020,000	1,000,000	1,000,000
Weighted average exercise price - vested and exercisable	'	'	'	$5.81	$2.50	$5	$10
Aggregate intrinsic value - vested and exercisable	'	'	'	'	$0	$0	$0

10_Stockholders_Equity_Details3

10. Stockholders' Equity (Details-Assumptions) (Stock Options, USD $)	12 Months Ended
	Dec. 31, 2013
Employees and Directors	'
Stock price	$0
Dividend yield	0.00%
Employees and Directors | Minimum	'
Contractual term	'1 year
Expected volatility	29.00%
Risk free interest rate	0.25%
Employees and Directors | Maximum	'
Contractual term	'5 years
Expected volatility	30.00%
Risk free interest rate	0.72%
Two Directors	'
Stock price	$2.50
Expected volatility	26.48%
Risk free interest rate	0.54%
Dividend yield	0.00%
Employee	'
Stock price	$2.50
Expected volatility	29.50%
Dividend yield	0.00%
Employee | Minimum	'
Contractual term	'3 years
Risk free interest rate	0.32%
Employee | Maximum	'
Contractual term	'5 years
Risk free interest rate	0.47%

10_Stockholders_Equity_Details4

10. Stockholders' Equity (Details-Warrants outstanding) (Warrant, USD $)	12 Months Ended
	Dec. 31, 2013
Warrant	'
Number of warrants	'
Warrants outstanding - beginning balance	0
Warrants granted	346,400
Warrants oustanding - ending balance	346,400
Warrants exercisable	346,400
Weighted average exercise price	'
Warrants outstanding - beginning balance	$0
Warrants granted	$3.22
Warrants outstanding - ending balance	$3.22
Warrants exercisable	$3.22
Aggregate intrinsic value	'
Warrants outstanding - beginning balance	'
Warrants granted	'
Warrants outstanding - ending balance	'
Warrants exercisable	'
Weighted average grant date fair value	$3.22

10_Stockholders_Equity_Details5

10. Stockholders' Equity (Details-Warrant assumption) (USD $)	12 Months Ended
	Dec. 31, 2013
Warrants issued total 46,400	'
Stock price	$0.01
Contractual term	'1 year
Expected volatility	29.13%
Risk free interest rate	0.15%
Dividend yield	0.00%
Warrants issued total 300,000	'
Stock price	$2.50
Contractual term	'2 years
Expected volatility	29.13%
Risk free interest rate	0.27%
Dividend yield	0.00%

10_Stockholders_Equity_Details6

10. Stockholders' Equity (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Shares repurchased, shares	40,000	'
Shares repurchased, cost	$100,000	$100,000
Shares issued in lieu of compensation, shares	25,000	'
Shares issued in lieu of compensation, value	62,500	225
Stock issued for acquisition, value	400,000	'
Stock based compensation	452,500	235,001
Convertible Series C Preferred Stock	'	'
Stock and warrants issued	203,233	'
Preferred stock Series B	'	'
Dividends earned	2,601,298	'
Dividends payable	360,726	'
Shares issued in lieu of compensation, shares	'	5,000
Nine investors	'	'
Stock and warrants issued	46,400	'
Proceeds from issuance of warrants	116,000	'
Two investors	'	'
Stock and warrants issued	68,000	'
Proceeds from issuance of warrants	$170,000	'

12_Income_Taxes_DetailsIncome_

12. Income Taxes (Details-Income tax components) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current provision:	'	'
Federal	$5,834,600	$1,702,200
State	1,027,500	181,700
Deferred provision:	'	'
Federal	-1,168,700	-1,267,200
State	-124,800	-135,300
Total	$5,568,600	$481,400

12_Income_Taxes_DetailsEffecti

12. Income Taxes (Details-Effective income tax rate)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Expected federal income tax at 34% statutory rate	34.00%	34.00%
State income taxes	4.30%	3.60%
Permanent differences	2.00%	3.50%
Change in valuation allowance	0.00%	-26.00%
Income tax provision (benefit)	40.30%	15.10%

12_Income_Taxes_DetailsDeferre

12. Income Taxes (Details-Deferred income taxes) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Allowance for bad debts	$1,362,900	$1,980,600
Accrued compensation	385,700	0
Stock options	170,300	0
Total deferred tax assets	1,918,900	1,980,600
Deferred tax liabilities:	'	'
Property and equipment	-76,100	0
Intangible amortization	-136,000	-36,100
Total deferred liabilities	-212,100	-36,100
Net deferred income taxes:	'	'
Current	1,748,600	1,980,600
Non-current	-41,800	-36,100
Net deferred tax	$1,706,800	$1,944,500

13_Business_Combinations_Detai

13. Business Combinations (Details-Goodwill (USD $)	Dec. 31, 2013	Dec. 31, 2012
Goodwill	$1,425,999	$1,050,912
Medical Billing Choices	'	'
Goodwill	1,202,112	802,112
PB Laboratories	'	'
Goodwill	107,124	107,124
Biohealth Medical Laboratory	'	'
Goodwill	$116,763	$141,676

13_Business_Combinations_Detai1

13. Business Combinations (Detail-Acquisition summary) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Consideration Given	'	'
Cash	$735,052	$101,000
Fair value of identifiable assets acquired and liabilities assumed:	'	'
Goodwill and unidentified intangible assets	1,425,999	1,050,912
International Technologies	'	'
Consideration Given	'	'
Cash	127,000	'
Amount due	483,052	'
Acquisition notes	500,000	'
Total consideration	1,110,052	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'
Cash	1,703	'
Property and equipment, net	31,649	'
Accounts payable and accrued expenses	-59,462	'
Notes payable	-529,167	'
Identifiable intangible assets	1,665,329	'
Total identifiable net assets	1,110,052	'
Goodwill and unidentified intangible assets	0	'
Total consideration	1,110,052	'
Alethea Laboratories	'	'
Consideration Given	'	'
Cash	125,000	'
Acquisition notes	575,000	'
Total consideration	700,000	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'
Cash	2,032	'
Property and equipment, net	92,498	'
Capital lease assets, net	392,817	'
Accounts payable and accrued expenses	-2,032	'
Notes payable	-344,650	'
Capital lease obligation	-415,949	'
Identifiable intangible assets	975,284	'
Total identifiable net assets	700,000	'
Goodwill and unidentified intangible assets	0	'
Total consideration	700,000	'
Biohealth Medical Laboratory	'	'
Consideration Given	'	'
Cash	100,000	'
Amount due	165,125	'
Acquisition notes	-24,913	'
Total consideration	240,212	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'
Cash	19,327	'
Property and equipment, net	64,206	'
Capital lease assets, net	9,477	'
Accounts payable and accrued expenses	3,143	'
Notes payable	-120,590	'
Capital lease obligation	-6,110	'
Identifiable intangible assets	275,000	'
Total identifiable net assets	244,453	'
Noncontrolling interest	-121,004	'
Goodwill and unidentified intangible assets	116,763	141,676
Total consideration	240,212	'
PB Laboratories	'	'
Consideration Given	'	'
Cash	1,000	'
Acquisition notes	400,000	'
Total consideration	401,000	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'
Cash	1,876	'
Property and equipment, net	17,000	'
Identifiable intangible assets	275,000	'
Total identifiable net assets	293,876	'
Goodwill and unidentified intangible assets	107,124	107,124
Total consideration	$401,000	'

14_Commitments_and_Contingenci2

14. Commitments and Contingencies (Details-Operating lease payments) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
2014	$333,656
2015	303,922
2016	178,461
2017	160,684
2018	116,350
2019 and thereafter	30,951
Total	$1,124,024

14_Commitments_and_Contingenci3

14. Commitments and Contingencies (Details-Purchase commitments) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
2014	$54,871
2015	54,871
2016	54,871
2017	54,871
2018	54,871
2019 and thereafter	109,742
Total purchase commitments	$384,097

14_Commitments_and_Contingenci4

14. Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'
Rent expense	$350,169	$134,733
Master equipment lease commitment	1,400,000	'
Uninsured cash	$2,631,000	$1,070,000

15_Pro_Forma_Financial_Informa2

15. Pro Forma Financial Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	$52,523,660	$21,076,357
Total operating expenses	38,023,670	17,545,404
Income (loss) from operations	14,499,990	3,530,953
Other income (expense)	389	129
Income (loss) before income taxes	13,828,517	3,228,355
Provision (benefit) for income taxes	5,568,600	481,400
Net income (loss)	8,259,917	2,746,955
Preferred stock dividends	2,601,298	50,000
Net income (loss) available for common shareholders	5,658,619	2,299,037
Net income per common share - Basic and diluted	$0.19	$0.07
Weighted average number of common shares outstanding during the period - Basic and diluted	29,654,703	30,795,073
Medytox Solutions, Inc. Historical	'	'
Revenues	52,523,660	'
Total operating expenses	38,023,670	'
Income (loss) from operations	14,499,990	'
Other income (expense)	-671,473	'
Income (loss) before income taxes	13,828,517	'
Provision (benefit) for income taxes	5,568,600	'
Net income (loss)	8,259,917	'
Preferred stock dividends	2,601,298	'
Net income (loss) available for common shareholders	5,658,619	'
Net income per common share - Basic and diluted	$0.19	'
Weighted average number of common shares outstanding during the period - Basic and diluted	29,654,703	'
International Technologies, LLC Historical	'	'
Revenues	2,943	'
Total operating expenses	305,183	'
Income (loss) from operations	-302,240	'
Other income (expense)	-1,343	'
Income (loss) before income taxes	-303,583	'
Net income (loss)	-303,583	'
Net income (loss) available for common shareholders	-303,583	'
Pro Forma Adjustments	'	'
Provision (benefit) for income taxes	-114,200	'
Net income (loss)	114,200	'
Net income (loss) available for common shareholders	114,200	'
Combined	'	'
Revenues	52,526,603	'
Total operating expenses	38,328,853	'
Income (loss) from operations	14,197,750	'
Other income (expense)	-672,816	'
Income (loss) before income taxes	13,524,934	'
Provision (benefit) for income taxes	5,454,400	'
Net income (loss)	8,070,534	'
Preferred stock dividends	2,601,298	'
Net income (loss) available for common shareholders	$5,469,236	'
Net income per common share - Basic and diluted	$0.18	'
Weighted average number of common shares outstanding during the period - Basic and diluted	29,654,703	'